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Abstract
Model-based analysis of cellular metabolism can facilitate our un-
derstanding of intracellular kinetics and aid the improvement of
cell growth and biological product manufacturing. In this thesis,
a model-based kinetic study of cytosolic glucose metabolism is pre-
sented. Based on the Kyoto Encyclopedia of Genes and Genomes and
the Braunschweig Enzyme Database, a metabolic map of cytosolic
glucose metabolism including 30 metabolites and 36 reactions, which
consists of glycolysis, glucogenesis, pentose-phosphate pathway and
adjacent metabolic reactions, has been constructed. Kinetic modelling
was performed according to this metabolic map and reported enzyme
kinetic studies, considering regulation and/or inhibition by products,
substrates or other metabolites. Parameters were estimated based on
previous parameter information and metabolic flux analysis studies, as
well as results from our own experiments. Simulation results for cell
population kinetics, metabolite concentrations and reaction rates have
shown good agreement with experimental data. Furthermore, in silico
case studies including global sensitivity analysis, feeding lactate as
a co-substrate and the regulation effect by fructose 2,6-bisphosphate
were performed in order to find strategies to increase metabolic effi-
ciency in Chinese hamster ovary cells in an attempt to provide a guide
for process optimisation. In conclusion, our model provides a deep
look into cytosolic glucose metabolism and the simulation results have
suggested a suitable direction to increase the metabolic efficiency.
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Chapter 1
Introduction
Biotechnology is based on the principle of recombinant DNA (rDNA) technology
developed by Paul Berg in 1972. [1] Biopharmaceuticals, including recombinant
proteins (e.g., monoclonal antibodies) and nucleic acids (e.g., DNA and RNA)
used in medical research, diagnosis, therapy, etc., [2] are medical drugs produced
by means of rDNA technology. Genentech, Inc., founded in 1976, is the world’s
first biotechnology company, and it is generally considered to have founded this
industry. [3] Genentech, Inc. developed the first biopharmaceutical, biosynthetic
‘‘human’’ insulin for therapeutic use, which was later manufactured and marketed
with the name of Humulin by Eli Lilly and Company. [4] The technology for
biopharmaceutical production has enjoyed a rapid development and the total
number of patents granted for biopharmaceuticals has increased significantly from
30 in 1978 to 34,527 in 2001. [5] There are new molecular entities and biologics
license applications approved by U.S. Food and Drug Administration (FDA) all
these years. [6]
After more than 30 years of global research and business expansion, the human
medical biotechnology industry was worth more than $32 billion in 2003 [7] and
is expected to grow to $144 billion by 2016. [8] More than 110 companies are
involved in the research and development, manufacture and marketing, and
there are over 80 therapeutics in clinical development and more than 73 licensed
products in market. [7] A typical example is the application of monoclonal antibodies
(mAbs) in cancer treatment by means of binding to cancer cell-specific antigens
correctly and inducing an immune response. According to U.S. pharmaceutical
23
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sales statistics, the total sales of bio-drugs in U.S. continued rising from $18.9
billion in 2002 to $51.3 billion in 2010 (see Figure 1.1, based on review papers by
Aggarwal [9--13]) From 2006, more than 100 biopharmaceuticals continue upward
sales with antibodies and insulin contributing high growth rates. [10] Research
and development (R&D) investment in new medicines by the biopharmaceutical
industry stood at $65.2 billion in 2008. [14]
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Figure 1.1: U.S. biological drug and mAbs sales and growth rates [9--13]
rDNA technology, the main vehicle used for biopharmaceutical production,
combines two or more sequences that would not normally occur together through
the process of gene splicing. By inserting the gene for the product of interest
into an active gene vector in a host cell line, when the genes in the vector are
transcripted into mRNA, the antibody genes are transcripted simultaneously,
hence antibodies are produced. To achieve high productivity, a typical cell line
has several important requirements:
• Efficient transcription of the antibody genes,
• Efficient translating of antibody mRNA,
• Sufficient secretory capacity,
• High and robust cell growth rate.
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Biopharmaceuticals may be produced from microbial cells, plant cells, moss
plants, and mammalian cell lines. Mammalian cell cultures are currently the
main process available for industrial production of biopharmaceuticals, such as
recombinant proteins and mAbs, [15] because mammalian cells are capable of
performing human-like post-translational modifications to the proteins that result
in full-active products. [16--18] The majority of drugs produced for therapeutic use
in humans are glycoproteins. Non-secreting 0 (NS0) cells and Chinese hamster
ovary (CHO) cells are the two most widely used mammalian cell lines in both
research and industrial production.
NS0 cells
NS0 cells is a murine myeloma cell line which does not secrete or synthesize
any heavy or light chains of immunoglobulin. It has been used for years as
a fusion partner for the production of hybridoma cells producing mAbs, and
recently, it became an important host cell line for producing recombinant
proteins.
CHO cells
CHO cells are used in biological and medical research and commercially in
the production of a large range of different proteins including antibodies,
enzymes, interleukins, membrane-bound proteins, etc. CHO cells are the
host cell line for over 70% of biopharmaceuticals on the market. [19] The
first FDA-approved drug produced in CHO cells was Activase for coronary
disease or cardiovascular disease developed by Genentech, Inc. in 1987. [20]
CHO cells are currently used as the preferred cell line for production because
they are robust and can achieve high specific protein productivities, but
also, because of the human-like post-translational modification they achieve.
There were 27 approved biologics produced in CHO cells in 2006, among
which 8 were mAbs, and the total annual sales exceeded USD 30billion. [19]
Glutamine synthetase expression system
Glutamine synthetase (GS) catalyzes the formation of glutamine (Gln)
from glutamate (Glu) and ammonia driven by ATP dehydrolysis in the
presence of Mg2`, and it is specifically inhibited by methionine sulfoximine
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(MSX). [21,22] Gln acts as a protein building block, an energy source and a
nitrogen donor in purine and thymidine synthesis. Cell lines that do not
produce GS have an absolute requirement for exogenous glutamine and do
not grow in glutamine-free culture media, which provides the basis for the
research in the GS systemTM as a selectable enzyme.
Figure 1.2: Reaction catalyzed by GS
Gene amplification has been achieved through the GS systemTM. It is used by
over 80 biotechnology and pharmaceutical companies and is currently employed
to produce 5 licensed products [23]. The natural function of this gene is to provide
glutamine for protein biosynthesis. Many myeloma and hybridoma cells like
NS0 cells and Agl4 cells do not have endogenous GS and are phenotypically
auxotrophic for glutamine, while many other cells like BHK-21 cells, L-cells, and
CHO cells have endogenous GS. [21] GS expression vectors designed for use in
murine NS0 cells and CHO cells are one of the most common expression methods.
CHO cells are capable of producing endogenous glutamine synthetase and do
not require glutamine provided in the culture medium, while NS0 cells do not
have endogenous glutamine synthetase and thus has an absolute requirement for
glutamine. [21] According to the experiments by Lonza Group, [24] GS-CHO and
GS-NS0 cells can produce up to 10 g{L and 2 g{L antibodies, respectively.
Although GS-CHO is a preferred cell line in biopharmaceutical production, the
metabolic pathways used by GS-CHO cells for glutamine synthesis are currently
unknown. The mAb productivity of GS-CHO is relatively high, but the previous
approaches to improve productivity through media and process design were mostly
based on trial-and-error or empirical research, which is inefficient, time-consuming
and costly.
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A kinetic model based on thorough understanding of intracellular metabolism
and inter-cellular relations is essential for the development of efficient bioprocesses.
It can provide insight to the cell culture’s nutritional needs and, hence, guide the
design of culture media, supplements and feeding strategies. This project aims to
build a kinetic model for cytosolic central glucose (Glc) metabolism in GS-CHO
cells using cell culture experimentation and metabolomics to drive its validation.
The structure of this thesis is as follows. Firstly, in Chapter 2, biological
principles are presented to underlay the system studied, following which previous
biological modelling work and experimental techniques are reviewed. Secondly,
based on online databases for metabolic pathway and enzymes, a mathematical
model of GS-CHO cells was established with the experiment for parameterization
as presented in Chapter 3. The parameter estimation and model simulation results
are shown in Chapter 6. Following this, in Chapter 7, case studies including
global sensitivity analysis, metabolism analysis and enzyme regulation analysis
are performed based on the validated model. A similar study then performed on
an industrially relevant cell line Saccharomyces cerevisiae in Chapter 8. In the
end, the conclusions and future outlook of the study are presented in Chapter 9.
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Chapter 2
Literature Review
Here, the biological principles for mammalian cells and metabolism were reviewed,
based on which the mathematical model for GS-CHO cells was built. Mathematical
modelling methods and previous modelling studies were also summarised as well
as the relative experimental techniques.
2.1 Biological Principles
2.1.1 Cell structure
Cells, fundamental units of terrestrial life, are small-scale but complex chemical
process plants. [25] Most of the biochemical reactions that support life activities
take place in cells which are the smallest units of life but are made up of inanimate
molecules. Cells can be divided into prokaryotes and eukaryotes. [25--27] The most
important distinction is that in prokaryotes there is no clearly defined, membrane-
bound organelle, and the structure is much simpler than in eukaryotes. Most
prokaryotic organisms are single-celled while most of the eukaryotic organisms are
multi-celled and have clearly defined nuclei and organelles. Prokaryotes include
various bacteria while eukaryotes include plants, animals, protists and fungi.
Although these different types of cells have quite different intracellular structures,
they are separated from prokaryotes because they have a well packed nucleus
with lipid bilayers. [25--27]
Unlike prokaryotic cells, eukaryotic cells are elaborately subdivided into func-
28
2.1 Biological Principles
tional distinctive, membrane-enclosed compartments, which are known as or-
ganelles. [25--27] The structure of an animal cell is presented in Figure 2.1.
Figure 2.1: Anatomy structure of an animal cell [28]
The major organelles for an animal cells include:
1. Nucleus
The nucleus, where most of the DNA and RNA are located, is covered by
nuclear membrane. RNA is synthesized in the nucleus on a DNA template
and transferred to the ribosome through the pores on the membrane. [25--27]
2. Mitochondria
The mitochondria are the second important organelle following the nucleus.
They have a smooth outer membrane and an inner membrane that has ruffles,
on which there are enzymes. The mitochondria are the place where the
metabolic reactions that supply the energy supporting cell activities taking
place. There are small amounts of ribosomal DNA inside the mitochondria
stroma. [25--27]
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3. Endoplasmic reticulum (ER) and ribosome
The ER has a lipid single layer structure with different shapes, e.g. tubular,
saclike and blisterlike, vesicles. It can be divided into two parts, rough ER
and smooth ER. There are many ribosomes on the rough-surfaced ER where
the proteins are synthesized. The ER is critical in protein synthesis and
initial stages of post translational protein processing. The ER also produces
the lipids for the rest of the cell and functions as storage for Ca2` ions. The
ER sends many of its proteins and lipids to the Golgi apparatus for further
post-translational modification. [25--27]
4. Golgi apparatus
The Golgi apparatus is formed by a series of smooth lipid single layer
membrane saclike vesicles. It takes part in the protein secretion process
and is also the site where the synthesis of polysaccharides, e.g., in mucus,
takes place. The Golgi apparatus is responsible for the completion of
complex glycosylation process of proteins and lipids and for collecting and
secreting extracellular proteins or directing intracellular protein traffic to
other organelles. [25--27]
5. Lysosome
The lysosomes contain various hydrolases such as protease, nuclease and
esterase, which are associated to the molecular breakdown. The lysosome
is responsible for the digestion of certain food particles ingested by the
cells. [25--27]
2.1.2 Cell growth profile
After decades of development, there are many methods to culture cells in vitro. Cell
culture techniques are used in food manufacture, biopharmaceutical manufacture,
R&D, etc. There are two major classes of operation methods, namely batch and
fed-batch. For batch culture, sufficient nutrients are supplied to the initial culture
media, and during the culture process, no inlet or outlet except air is applied.
Fed-batch allows nutrient inlet during the culture process. Typically, as shown in
Figure 2.2, a standard batch cell growth curve includes the following 4 phases:
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1. Lag phase: the cells adapt themselves to the new environment,
2. Exponential phase: rapid cell proliferation,
3. Stationary phase: the growth rate slows as a result of nutrient depletion
and accumulation of toxic products,
4. Death phase: apoptosis is dominant.
Figure 2.2: Sketch of a typical batch cell culture growth curve
2.1.3 Metabolic pathways
Cell metabolism consists of catabolism and anabolism. A metabolic pathway is
made up of a series of ordered enzymatic reactions and it represents a synthesis
process or a degradation process of a biochemical molecule. Except for the
externally supplied initial reactants like Glc, all other reactants, intermediates
and products are called metabolites. Most of the products of upstream reactions
are the reactants of the downstream reactions.
Catabolic processes decompose macromolecules to small construction molecules
and produce energy for cell activities, while anabolic processes synthesize macro-
molecules, such as proteins, and consume energy. Energy is also consumed by
some other activities like transmembrane transport and cell movement. However,
anabolism is never the simple reverse of catabolism. Although metabolism is
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important to the whole cell activities, the metabolic pathways mainly occur in
certain particular zones, most importantly in the cytosol and the mitochondria.
Metabolism is highly controlled to adapt to changing environments to maintain
cell activities.
Among the complex global metabolic pathways, Glc metabolism is only a
small part. However, Glc is the main carbon donor and an important energy
supplier for most cells. Glc metabolism is therefore one of the most important
part of the whole metabolic activities. Glc metabolism, sometimes called central
carbon metabolism, consists of 3 steps:
1. Glycolysis, shown in Figure 2.3, which takes place in cytosol, is the pathway
of Glc degradation through 10 coupled enzymatic reactions producing two
molecules of pyruvate and two molecules of ATP per Glc molecule. Glycolysis
is the best understood metabolic pathway. [27]
2. The pentose-phosphate pathway (PPP) produces ribose 5-phosphate
and NADPH, which are used for nucleic acid synthesis and reductive biosyn-
thesis, respectively (Figure 2.4). Furthermore, the PPP produces the pre-
cursors of several amino acids via phosphoribosyl pyrophosphatey.
3. The tricarboxylic acid (TCA) cycle (sometimes known as the citric acid
cycle or the Kreb’s cycle) is the pathway of complete pyruvate oxidation
to CO2 and H2O. In eukaryotic cells, the TCA cycle takes place in the
mitochondria. The pyruvate molecule, which is produced in the cytoplasm,
is transferred into the mitochondria through the mitochondrial membrane.
In the mitochondrial stroma, pyruvate firstly turns into CO2 and acetyl
CoA, and then enters the TCA cycle for further oxidation, as shown in
Figure 2.5.
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Figure 2.3: Metabolic map of glycolysis [29]
2.1.4 Enzyme kinetics
Enzymes are biological molecules that catalyse the chemical reactions by means of
increasing the reaction rates. They are mostly large proteins and RNA. Enzymes
are involved in almost every biological reaction in cells. They are highly specific,
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Figure 2.4: Metabolic map of pentose-phosphate pathway [30]
versatile, and efficient. They only catalyse one or a few similar reactions. In
most cases, metabolic pathways can be represented by a set of enzymes and their
substrates and products.
Enzymes work like all catalysts by adjusting the activation energy (Ea) for the
reactions they catalyse and enzymes are highly specific. A non-protein group is
needed for enzymatic reactions sometimes, and this group is either a cofactor such
as a metal ion or a co-enzyme such as an organic molecule. Enzyme activity can
be regulated by other molecules, such as inhibitors that decrease enzyme activity,
or activators that increase enzyme activity. Enzyme activity is also affected by
temperature, pH.
Michaelis-Menten kinetics, proposed in 1913 by Michaelis and Menten, [32] is
one of the best-known models of enzyme kinetics. The reaction scheme can be
described as:
E` S k1ÝÝáâÝ
k´1
ES
kcatÝÝÑ E` P
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Figure 2.5: Metabolic map of TCA cycle [31]
where E, S, ES and P denote enzyme, substrate, enzyme-substrate complex and
product, respectively. Based on the rapid equilibrium assumption, where enzyme
and enzyme-substrate complex are assumed to reach equilibrium [32], the reaction
rate v can be written as:
v “ VmaxrSs
Km ` rSs , (2.1)
where Michaelis-Menten constant Km and maximum reaction rate Vmax follows
Km “ k1
k´1
and Vmax “ kcat rEs0 .
where rEs0 is total enzyme concentration.
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Enzyme activities can be adjusted due to several factors, e.g., pH, temperature,
etc. When enzymes are allosterically regulated, i.e., they have more than one
binding site, the binding of one substrate can facilitate further substrate binding.
The rate expression for allosteric enzymes therefore is
v “ VmaxrSs
n
Knm ` rSsn , (2.2)
where n is the Hill coefficient.
Some compounds can bind to the enzymes and reduce their activity, which is
called enzyme inhibition. This can be reversible or irreversible. Mechanism of
reversible inhibition can be described as:
E ` S KmÝÝáâÝ ES Ñ E` P
` `
I I
êKi êK1i
EI ` S KmÝÝáâÝ ESI
where I, EI and ESI denote inhibitor, enzyme-inhibitor complex and enzyme-
substrate-inhibitor complex, respectively. There are five major classes of reversible
inhibition:
1. Competitive inhibitors can only bind to the enzyme, and the reaction rate
is:
v “ VmaxrSs
Km
´
1` rIs
Ki
¯
` rSs
. (2.3)
2. Non-competitive inhibitors can bind to enzyme and enzyme-substrate
complex with the same affinity, i.e. Ki “ K 1i, and the rate is:
v “ VmaxrSs
pKm ` rSsq
´
1` rIs
Ki
¯ . (2.4)
3. Uncompetitive inhibitors can only bind to enzyme-substrate complex, and
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the reaction rate is:
v “ VmaxrSs
Km ` rSs
´
1` rIs
K1i
¯ . (2.5)
4. Mixed-type inhibitors can bind to enzyme and enzyme-substrate complex
with different affinity, i.e. Ki ‰ K 1i, and the reaction reaction rate is
v “ VmaxrSs
Km
´
1` rIs
Ki
¯
` rSs
´
1` rIs
K1i
¯ . (2.6)
5. Substrate inhibition is a special case where the substrate acts as an inhibitor,
and the reaction rate in this case is
v “ VmaxrSs
Km ` rSs ` rSs2Ki
. (2.7)
2.1.5 Transmembrane transport
Membranes divide the cell into several different compartments. The transport
through membrane can be classified into various types but largely there are two
main categories: passive transport and active transport.
Passive transport relies on concentration gradients across membranes to drive
the diffusion process. Michaelis-Menten kinetics are often used for passive trans-
port, which can be divided into three different subclasses:
1. Passive diffusion— simply transport through the membrane without any
proteins, reactions and energy. The transport rate is directly proportional
to the concentration gradient. Fatty acids and non polar molecules are the
typical molecules that use this mechanism.
2. Facilitated diffusion requires a specified transport protein through which
the molecules/ions are transported. The transport proteins are gated chan-
nels that can regulate the transport rates.
3. Exchange diffusion is a diffusion that leads to a counter-direction trans-
port of another molecule. Such diffusion contributes to the balancing of the
concentration gradient.
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Active transport requires energy to transport through the membrane against
a concentration gradient or to increase the transport rate. Ion and pH gradients
may be associated with this type of transport. Active transport is used to uptake
amino acids, with each amino acid transported through different group of transport
proteins and subject to competitive inhibition by other amino acids with similar
structure.
Wu et al. [33] proposed a classification that divides amino acids in CHO cells,
for the purpose of mathematical modelling, into two groups: L system (Leucine
(Leu) preferring, preferred by essential amino acids) and A system (Alanine
(Ala) preferring, preferred by non-essential amino acids). [33] The L system is
characterized by exchange diffusion while the A system follows the principle of
irreversible transport. Based on identical mode of transport, and following the
grouping for amino acids developed by Wu et al. [33], Sanderson grouped the amino
acids into 8 categories and the driving force for amino acids is considered in the
way of groups. [34]
2.2 Modelling of cell culture processes
Mathematical modelling is a useful tool for researchers as a well-developed model
can reduce the high experiment cost and time. However, a thorough understanding
of the system and a predictive model are essential. Due to the escalating cost of
bioprocess experiments, modelling of biosystems has gained increasing attention.
Before building a model, one important thing for the developers is to decide which
type of model to built, depending on application and data availability.
There are many biological relevant databases existing today for DNA, enzyme
kinetics, etc., which are useful for MNR and kinetics data-mining. Here, the
existing databases are summarised in Table 2.1.
2.2.1 Modelling methods
There are three key points in cell culture process modelling that require attention,
namely integrity, structure and randomness. [35,36] There are two levels in the
cell culture environment: the macroscopic level, which includes the media, that
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Table 2.1: List of biological databases
Group Name
Genome Biochemical Genetic and Genomic knowledgebase
BioCyc pathway/genome databases
Chemical Entities of Biological Interest
DNA Data Bank of Japan
European Bioinformatics Institute
Expert Protein Analysis System
Gene Ontology
Kyoto Encyclopedia of Genes and Genomes
National Center for Biotechnology Information
Profils pour l’Identification Automatique du Me´tabolisme
Reactome (pathway database)
Swiss Institute of Bioinformatics
Enzyme Braunschweig Enzyme Database
Integrated relational Enzyme database
ExplorEnz Enzyme Database
Others BioModels Database
Model Seed
Worldwide Protein Data Bank
act as a bridge between individual cells and the reactor environment, and the
microscopic level, which deals with individual cells.
The main families of macroscopic level modelling are segregated and unsegre-
gated. Unsegregated models treat the population as a whole biological phase, i.e.,
homogeneous, with the average cell used to represent all the cells in the system.
In contrast, segregated models treat the cell population as divided into different
subpopulations that vary from one another in a certain important variable, such
as cell age, cell mass or cell cycle position. For example, segregated models can be
based on the mammalian cell cycle, [37] which are related to the growth kinetics
and metabolic activities.
The main families of microscopic level modelling are structured and unstruc-
tured. Unstructured models treat the cells as single components without any
internal structure but only consider the change of cellular physiological state
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depending on the environment. [38] On the contrary, structured models assign
different structures in the cells such as cell organelles. The intracellular com-
partments and the interaction between the compartments are introduced to the
model. Although structured models can describe cell activities in more realistic
terms, they may require significantly more equations than unstructured models,
which makes the model more complex to validate due to the need of intracellular
measurements.
The key difference between stochastic and deterministic modelling is whether
the progression of the bioprocess of the cell allows for random activities. De-
terministic models are based on all bioprocesses following fixed routes, while
stochastic models permit random deviations. Most of current modelling efforts
in cell metabolism and culture are deterministic. Stochastic method is used
when molecule number is small and mitosis that involves random chromosome
segregation is a typical stochastic process.
2.2.2 Metabolic modelling
Metabolic network reconstruction (MNR) is a methodology for defining the series
of biochemical reactions, related enzymes, substrates and products that consti-
tute an organism’s metabolism. It is typically the first step towards simulating
the metabolism. An MNR protocol has been described by Palsson’s group re-
cently, [39,40] in which the methods of using experiment and data to generate a
metabolic reconstruction were summarised. Based on the available genomic data
and using homology studies for unknown reactions in the genome, the biological
reaction network could be identified which could be used for model building.
Chen et al. [41] reviewed advances in MNR and discussed the opportunities and
challenges for the experimental validation of the model, as shown in Figure 2.6.
Under the principle of mass balance, for a system that has n metabolites and m
reactions, we can have the following general equation for mass conservation:
dci
dt
“
mÿ
j“1
si,j ¨ vj, for i “ 1, ¨ ¨ ¨ , n. (2.8)
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Purpose of the model:
• prediction of growth rates
• prediction of product yield
• metabolic engineering
• explanation/organisation of experimental data
• define targets for drug discovery
Genomic databases
Metabolic Network and 
Metabolic compounds 
Databases
Protein & 
Enzyme 
Databases
Metabolic model 
repositories Experimental 
Data repositories
Draft of desired 
network 
EXISTING DATA
Select type of model
• Kinetic 
• Stoichiometric
Missing Data [structural, i.e. missing nodes-
metabolites, dead- end metabolites]
Manual curation
In silico analysis
Identify experimental 
data needed  (D.O.E.)
Optimally 
informative 
experiments
Refined model
structural 
analysis
functional 
analysis
Final model
More experimental 
data from the studied 
system
•Genome sequence
•Similarity-based 
annotation
•Regulatory data
•Metabolic data
•Biochemical data
•Protein interaction data
•Deletion phenotyping
•Metabolomics
•Fluxomics
•Transcriptomics
Figure 2.6: Schematic overview of metabolic network reconstruction process,
experimental data required and potential applications [41]
There are two families of models developed based on MNR, i.e., stoichiometric
and kinetic models.
Stoichiometric models assume the system to be at (quasi-)steady state. How-
ever, there are usually more reactions than compounds. Therefore, stoichiometry
matrix s is under-determined, and there will be an infinite number of linearly
independent solutions. In order to solve the equation, biological meaningful
constraints need to be introduced to the system. There are many methods to
solve the problem which can be sorted into the following three categories: [42]
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1. Metabolic flux analysis (MFA) is a method that separates the reaction
rate vector into one measurable and another unmeasurable flux vector and
solves the unmeasured fluxes based on the measured fluxes. Main task in
this method is to acquire enough flux data to calculate the unmeasured
ones. Isotope labelling is often used as the flux measurement technique.
Commonly used isotopes include 1H, [43,44] 2H, [44] 13C, [44--48] 14N, [44] 15N, [43,44]
etc. However, the nonlinearities in isotope balances make it difficult to
guarantee that even a seemingly encompassing set of measurements can
uniquely determine all fluxes.
2. Flux balance analysis (FBA) is a widely-used approach for studying
metabolic networks. [49] It uses linear programming (LP) to obtain a unique
solution by employing an objective function based on convex analysis. The
objective function can include biomass yield, [50] evolutionary pressure, [51]
total flux weighting [52] or adaptation to extracellular conditions, e.g., hy-
poxia. [53--55] The key approach of the method is to find out the most repre-
sentative objective function for the system at hand.
3. Metabolic pathway analysis (MPA) relies on additional constraints
such as non-decomposability and systematic independence, other than flux
measurements. Two different applications were put forward recently, namely
elementary mode analysis (EMA) and extreme pathway analysis
(EPA). [56] Elementary mode analysis introduces a non-decomposability
constraint to the system. This ensures that each solution (namely elementary
mode) is unique and that it translates into a minimum set of enzymes to
support steady state operation. Extreme pathway analysis introduced a
constraint to make all extreme pathways systematically independent, which
means extreme pathways cannot be expressed as a non-negative combination
of any other extreme pathways. Extreme pathway analysis is a subset of
elementary mode analysis. [56,57]
In contrast to stoichiometric models, detailed kinetic models represent the
metabolite interactions that occur during the reactions catalysed by enzymes. Ki-
netic models are constructed based on enzymatic kinetics and are time-dependent,
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represented by a system of mass balance equations and algebraic reaction rates.
Kinetic models are able to study cell activities more realistically. By introducing
the regulation effects, kinetic models are more suitable for optimising the culture
condition and media formulation.
However, due to the lack of kinetic data, simplified kinetic modelling is often
performed by grouping metabolites, e.g., grouping amino acids into essential and
non-essential, [33] and reactions, e.g., grouping glycolysis reactions from Glc to
lactate (Lac) as one reaction. [33]
2.2.3 Previous modelling studies
Bibila and Flickinger [58] developed a structured kinetic model for antibody synthe-
sis and secretion in order to optimise the antibody production system in steady-
state level by hybridoma cells in steady-state and fed-batch, respectively. Jang
and Barford [59] developed an unstructured, unsegregated and kinetic model models
for antibody synthesis which describes the cellular macromolecule metabolism
using Glc and Gln as growth substrate, and ammonia and Lac as growth inhibitor.
Tatiraju et al. [60] used an unstructured and unsegregated model to make a real-
time, multi-rate, non-linear state and parameter estimation, in which cell growth
depends on three essential nutrients: Glc, Gln and oxygen. Kontoravdi et al. [61]
developed an unstructured, unsegregated, deterministic and kinetic model models
for cell growth and death kinetics as well as metabolism of Glc and amino acids
for CHO cells and HEK-293 cells.
Tziampazis and Sambanis [37] reviewed the growth and death kinetics, and
discussed the effects of Glc, Gln, dissolved oxygen, Lac and ammonia in detail
for suspended cells, adherent cells and cell-aggregate cultures. They addressed
that cell culture models should be based on the underlying physical mechanisms
whenever possible, and extrapolation cannot be used in a model that is only built
to fit certain sets of data (an unstructured model). However, they admitted that
for some complex systems that the related knowledge is insufficient. Some novel
knowledge of mathematics modelling, like neural network model, is quite useful
in building a validated model.
Po¨rtner and Scha¨fer [62] reviewed 11 different growth and death kinetics that
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treated the model in different aspects. Different nutrients lead to cell growth like
Glc, amino acids and different toxins lead to cell death like Lac and ammonia are
all discussed in detail. It is found that because of that the modelling problem or
metabolic changes or lack of thorough understanding in metabolism, hybridoma
cell culture modelling inheres a considerable error and a certain unpredictability.
To minimize the error of the model, some important aspects should be considered.
When calculating the specified growth rate, a careful medium composition study
should be made rather than simply using Glc and/or Gln as most of the existing
models. For the inhibition effect, although the effect of Lac and ammonia is quite
commonly used, the kinetics used in the existing models vary significantly. They
also suggested that when choosing model types, a continuous culture (chemostat)
is suitable for high substrate concentrations as well as a fed-batch culture is
reliable for low substrate concentrations.
As an application of the reported genome and genome-based model, Jerby et
al. [63] built a tissue-specific model for human liver cells from a reported generic
genome-based model of human metabolism by factoring reconstruct the reaction
network. Furthermore, as the kinetics data are mostly from different sources, in
order to reduce time for model reconstruction, Li et al. [64] proposed a workflow
named Taverna for automated assembly of metabolic networks in Systems Biology
Markup Language (SBML), [65] which is a tool used by many researchers linking
different biochemical network models.
Lee and Viot [66] presents a mathematical kinetic model for monolignol biosyn-
thesis in Populus xylem, which included metabolic map construction and flux
balance analysis as a steady-state flux distribution. Dynamic parameter esti-
mation was performed based on the steady-state flux distribution, metabolite
concentrations, and enzyme kinetic data.
It is quite clear that a segregated, structured model represents the most realistic
option. Three typical types of model are single cell model (SCM), population
balance model (PBM) and cell ensemble mode (CEM). PBM is a segregated model
that considered the cell population distribution, while SCM is unsegregated and
structured. Both PBM and SCM are two widely accepted models by researchers
and significant relevant work has been carried out. CEM is an alternative approach
for constructing structured cell population models other than PBM.
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1. SCM
Wu et al. [33] developed a structured, kinetic model of a growing single CHO
cell. In this work, 18 metabolic components were considered and amino
acids were grouped into essential amino acids and non-essential amino acids.
Major metabolic pathways and three transport mechanism were described
in this work. After this work, Sanderson [34] introduced a larger SCM. It
has general applicability to any type of suspension culture of mammalian
cells. Cellular compartmentalization and transmembrane transport were
introduced. Sidoli et al. [67] developed a single-cell model based on the work
by Sanderson. [34] The model comprises the cytoplasm and the mitochondria,
which relate directly to the cellular compartments and are coupled to a
model that simulates the cell environment. Sabate et al. [68] presented a
kinetic single cell metabolic model but only for the PPP. Nolan and Lee [69]
recently presented a dynamic single cell model of CHO cell metabolism, the
whole cellular metabolism was represented by 34 kinetic reactions including
Glc metabolism, amino acid metabolism, transmembrane transports for Glc,
Lac, ammonia, amino acids, biomass and antibodies.
A recent trend of single cell modelling is to try to cover a large part of
the metabolic map. Using SBML, Palsson’s group [70] built a large-scale
metabolic model consists of 1761 reactions and 1168 metabolites. Smallbone
et al. [71] presented a metabolic model based on the stoichiometry and linlog
kinetics and later they [72] improved the model using SBML into a large-scale
parameterized genome-scale kinetic model of a metabolic network including
956 reactions and 820 metabolites for yeast, which was based on the existing
kinetic models of constituent metabolic pathways from BioModels database.
2. PBM
Population balance model can be used to keep track of large numbers of
entities, irrespective of which system is used. [73] Generally, PBM is used for
particular processes in which the particle state has been restricted to a point
defined by some physical parameters. In cell culture modelling, this entity is
the cells in the system. Cell cycle position, cell size, etc. are all criteria that
are used to divide the cell population into subpopulations. It describes the
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behavior of single cells in the company of its fellow cells. Mantzaris et al. [74]
designed a mass structured cell population balance model with a one-step,
explicit, finite difference scheme, which was developed for the solution of
the mass structured cell population balance in an environment of changing
substrate concentration. Sidoli et al. [67] also coupled the aforementioned
SCM with a PBM. The SCM is used to characterize the cell growth and
death functions while the PBM is employed to capture the segregated cell
population.
3. CEM
In a cell ensemble model, the cell population is divided into a large number of
single cell models based on key cellular properties like cell mass or cell cycle
position. It is based on the assumption that the PBM can be approximated
and represented by a large number of single cells. [75] Shuler’s group [76--78] has
achieved the modelling of continuous culture for E. coli using cell ensemble
model with about 250 individual cells. The advantage of cell ensemble model
compared to PBM is that it can be directly integrated with the SCM and
reduce the computational difficulties.
2.2.4 Discussion
A kinetic model is needed in this project to analyse the intracellular metabolic
behavior. However, the previous kinetic SCMs are not suitable and have their
disadvatanges. The SCMs presented by Wu et al., [33] Sanderson, [34] and Nolan
and Lee [69] simplifyed the intracellular metabolic network and lost the capability
of analyse the contribution of each metabolite or enzyme. The SCMs presented by
Palsson’s group [70] and Smallbone et al. [71,72] built large-scale models and covered
large parts of the metabolism. But these models do not have detailed kinetic
information for process improvement.
The inspiring detailed model for the PPP by Sabate et al. [68] is capable
of analysing the detailed metabolic behaviors. The transmembrane transport
suggested by Nolan and Lee [69] is capable of linking intracellular and extracellular
environments kinetically.
With no doubt, PBM represents more realistic cell culture behavior. However,
46
2.3 Sensitivity analysis
a realiable PBM requires detailed information about the cell size and cell stage
information, which requires a significant amount of work to generate the data for
model parameterization. Hence, for the project, all cell sizes were assumed to be
the same.
2.3 Sensitivity analysis (SA)
SA is the study of how much the uncertainty of inputs of the model will contribute
to the uncertainty of the outputs. [79] In other words, SA is the study of the
relationship between the inputs and outputs of a model. Evaluation of confidence
in the model is an important consideration in the development of high-fidelity
models. [79]
An important goal of SA in biological modelling is to investigate the impor-
tance of each parameter in the model. The results can be used to guide model
validation and model reduction. [79] SA is proven to be a useful tool in kinetic
model studies [80,81] and in a cell culture model, [82,83] SA will be useful for model
building and culture improvement.
Consider a model described by a function u “ f pxq, where x “ px1, ¨ ¨ ¨ , xnq
is defined in a n-dimensional unit interval hypercube In “ r0, 1sn. m-dimensional
arbitrary set y “ pxk1 , ¨ ¨ ¨ , xkmq, for 1 ď k1 ă km ď n and 1 ď m ď n ´ 1, is a
subset of x, while z is the complement of y in x. It has been recently applied to
cell culture modelling. [79]
1. Screening is a qualitative method, [79] the use of which is limited to first
order results. It is considered to be imprecise for nonlinear models. [83]
2. Local sensitivity analysis (LSA) is usually carried out by computing
the partial deviation of the output functions with respect to the input
variables [79] as the following equation: [84]
Ei pxq “ Bf pxqBxi
ˇˇˇˇ
x
. (2.9)
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The local sensitivity indices Ei pxq can be estimated as
Ei pxq « f px1, x2, ¨ ¨ ¨ , xi´1, xi ` δ, xi`1, ¨ ¨ ¨ , xn´1, xnq ´ f pxq
δ
, (2.10)
where δ is a small increment, e.g., δ “ ˘5%xi. [85]
3. Global sensitivity analysis (GSA) is the method for considering the
sensitivity over the whole parameter space. Sobol’ described a GSA study
which used Monte Carlo methods on nonlinear mathematical models in
detail. [86] This was then used by Kontoravdi et al. to performe a GSA study
on a mAbs production model for experimental design. [82] Unlike the LSA
approach which is shown in Equation 2.9, the GSA approach does not need
to specify the input x, but considers the model itself. [86] There are three
common class of GSA methods, namely Sobol’ global sensitivity indices
(SI), the elementary effects (EE) (commonly called Morris method) and
derivative based global sensitivity measures (DGSM).
(a) SI
SI [86] is based on ANOVA (analysis of variance) representation of
function u “ f pxq:
f pxq “ f0 `
nÿ
s“1
nÿ
1ďi1ă¨¨¨ăisďn
fi1¨¨¨is pxi1 , ¨ ¨ ¨ , xisq. (2.11)
Assume that f pxq is square integrable and then all fi1¨¨¨is are also
square integrable andż
In
f 2 pxq dx´ f 20 “
nÿ
s“1
nÿ
i1ă¨¨¨ăis
ż
In
f 2i1¨¨¨isdx1 ¨ ¨ ¨ dxs, (2.12)
The individual variances and total variances terms are defined as:
Di1¨¨¨is “
ż
In
f 2i1¨¨¨isdx1 ¨ ¨ ¨ dxs and D “
ż
In
f 2 pxq dx´ f 20 .
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The individual global sensitivity indices are defined as the ratios
Si1¨¨¨is “ Di1¨¨¨isD ,
which are normalized Di1¨¨¨is . Hence, the individual global sensitivity
indices for element xi and subset y are
Si “ Di
D
and Sy “ Dki¨¨¨km
D
.
Besides individual sensitivity indices, the total sensitivity indices are
defined as
Stoty “ 1´ Sz.
(b) EE
The elementary effects are defined as:
EEi pxq “ f px1, ¨ ¨ ¨ , xi´1, xi `∆, xi`1, ¨ ¨ ¨ , xnq ´ f pxq
∆
,
where
∆ P
"
1
p´ 1 ,
2
p´ 1 , ¨ ¨ ¨ ,
p´ 2
p´ 1
*
,
x P
"
0,
1
p´ 1 ,
2
p´ 1 , ¨ ¨ ¨ ,
p´ 2
p´ 1 , 1
*n
and xi ď 1´∆.
The distribution of EEi pxq is denoted as Fi, whose mean and standard
deviation are denoted as µi and σi, respectively. Both µi and σi are
used as criteria of global sensitivity analysis.
Because of the difficulty of handling two criteria, a revised EE (rEE)
method [87] has been proposed using |EEi pxq|, the distribution of which
is denoted as Fi˚ , whose mean µi˚ is as the sole criterion.
µi and µi˚ are the approximation of
µi «
ż
In
Bf pxq
Bxi dx. (2.13)
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µ˚i «
ż
In
ˇˇˇˇBf pxq
Bxi
ˇˇˇˇ
dx. (2.14)
(c) DGSM
The DGSM method takes the local sensitivity indices Ei pxq and average
them over the parameter space. [88] Three nominal point independent
measures are defined:
M¯i “
ż
In
Ei pxq dx, Σ¯i “
dż
In
E2i pxq dx´ M¯2i
and Gi “ Σ¯2i ` M¯2i “
ż
In
ˆBf pxq
Bxi
˙2
dx.
And for subset y,
Gy “
mÿ
i
Gki .
Normalized G is often used as the criteria for global sensitivity analysis:
G¯i “ Giřn
j Gj
and G¯y “
řm
i Gkiřn
j Gj
.
Based on Taylor expansion, a revised DGSM (rDGSM) method [89] is
proposed as:
τi “
ż
In
ˆBf pxq
Bxi
˙2
1´ 3xi ` x2i
6
dx and τy “
mÿ
i
τki
which are improved Gi and Gy, but closer to D
tot
i and D
tot
y .
[89]
Similarly, normalized τ are:
τ¯i “ τiřn
j τj
and τ¯y “
řm
i τkiřn
j τj
.
SI and DGSM can be estimated by using the Fourier amplitude sensitivity
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test (FAST) [90,91] and Sobol’ (quasi-)Monte Carlo methods. [86] There has
long been debate on the advantages and disadvantages of the FAST and
Sobol’ quasi-Monte Carlo method. The mathematical ease and transparency
of higher order effects calculation offers Sobol’ quasi-Monte Carlo method
preferable over FAST. [83,92] It has, however, been shown that there is a
relationship between DGSM and Sobol’ sensitivity indices and that DGSM
is easier to implement mathematically and computational expensive. [88] The
GSA methods are summarized in Table 2.2. To some extent, DGSM is the
generalization of the EE methods. It is also shown in literature [83,93] that
there is a link between Stoti and Gi.
Latin hypercube sampling (LHS) is used for the estimation of the EE. [87]
Table 2.2: Comparison of the GSA methods
Method Criteria for y (unnormalized) Sampling Comput. cost
SI
ż
In
f 2k1¨¨¨kmdxk1 ¨ ¨ ¨ dxkm MC/qMC 3Nn
EE
mÿ
i“1
ż
In
Bf pxq
Bxki
dx
˚
, σk1 , ¨ ¨ ¨ , σkm LHS N pn` 1q
rEE
mÿ
i“1
ż
In
ˇˇˇˇBf pxq
Bxki
ˇˇˇˇ
dx
˚
LHS N pn` 1q
DGSM
mÿ
i“1
ż
In
ˆBf pxq
Bxki
˙2
dx MC/qMC N pn` 1q
rDGSM
mÿ
i“1
ż
In
ˆBf pxq
Bxki
˙2 1´ 3xki ` x2ki
6
dx MC/qMC N pn` 1q
˚ Approximation
As in this study the variable and parameter numbers is much higher than
the model shown in [82,83]. Hence, for the reason of computational ease,
DGSM is method is chosen as for sensitivity analysis.
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2.4 Metabolomics analysis
2.4.1 Technique overview
Metabolomic analysis is a key technique of this project used for kinetic parameter
estimation and model validation. A generic protocol for metabolomic analysis
is presented in Figure 2.7. A basic protocol consists of three steps: quenching,
extraction and analysis. Here the available techniques and recent advances in
quenching, extraction and analysis methodologies were examined.
Figure 2.7: Overview of metabolomic analysis protocol (adapted from [94])
A consideration in metabolomic analysis is to break the cellular membranes and
keep the metabolite pools concentrations the same as at sampling time. So stopping
the reactions (quenching) and breaking the cell membranes (extraction) are without
losing materials are key steps towards accurate analysis. Proper quenching is
capable of keeping metabolome the same as at sampling time. Literally, quenching
means rapid cooling. In biological experiments, quenching is a useful technique for
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intracellular analysis, because cellular activity (metabolism) stops rapidly without
being damaged at low temperature. [95] Rapid turnover rates for many enzymes
necessitate the quenching process prior to metabolome extraction. [96] Turnover
rates of enzymes decrease when temperature drops and the quenching process is
more efficient when temperature is lower.
Extraction is a group of methods for breaking the cell membranes, including
sonication, flash freezing, etc. Solution selection is crucial for quenching and
extraction, and different quenching and extraction solutions can result in different
results. [96] Cell extraction analysis is often achieved by coupling chromatography
and spectroscopy techniques, which is a combination of a separation step (chro-
matography) and a molecular recognition/quantification (spectroscopy). In terms
of sensitivity and separation power, the most promising technique is coupling the
chromatographic separation of metabolites and the selective detection in a mass
spectrometer (MS). [97]
Furthermore, for parameterisation for the biological model, another important
information besides dynamic metabolome is the dynamic metabolic flux rate, which
generally performed by applying isotope labelled to the culture and monitoring
the changes in labelled metabolites. Ahn and Antoniewicz [98] reviewed the MFA
techniques for CHO cell cultures and presented a MFA study for Glc metabolism
including glycolysis and the TCA cycle for both exponential phase and early
stationary phase in fed-batch CHO cell culture in which 13C labelled Glc was
added every 2 days, and the samples were analysed using GC/MS. [99]
2.4.2 Current studies
Sellick et al. [95] performed a metabolic analysis study for GS-CHO cells, same
host cell line as this project, and compared different quenching methods for their
efficiency at ´40 ˝C, namely methanol (MeOH), MeOH+4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), MeOH+ammonium bicarbonate (AM-
BIC), MeOH+NaCl and centrifugation. Specifically, four different quenching
solution were compared and mixture of 60% methanol with 0.85% pw{vq AMBIC
(pH 7.4) has proven most suitable for ATP, NAD` and G6P. 100% methanol
was used as extraction solution. Flash freezing in liquid nitrogen (boiling point
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´196 ˝C) and fast heating on ice at 4 ˝C were used to break the cell mem-
branes. ATP, ADP, AMP and NAD`/NADH were analysed by specific assay
kits, Glc 6-phosphate by NAD`/NADH conversion, Glc by HPLC and refractome-
ter, other metabolites by gas chromatography time-of-flight mass spectrometry
(GC-TOF-MS).
Dietmair et al. [96] compared three quenching solutions, namely (1) 60% MeOH
at ´40 ˝C, (2) ´40 ˝C MeOH buffered with 0.9% AMBIC and (3) 0.9% NaCl
at 0.5 ˝C, twelve extraction solutions, namely acetonitrile (ACN), MeOH, cold
50% MeOH, MeOH/Chloroform, hot 80% MeOH, cold 100% MeOH, hot ethanol
(EtOH), hot EtOH+HEPES, cold EtOH, hot H2O, KOH and perchloric acid (PCA),
and the separation techniques of centrifugation and filtration for mammalian cells.
Results showed that cold isotonic saline (0.9% pw{vq NaCl, 0.5 ˝C) quenching-fast
filtration-50% aqueous ACN extraction was superior than others. The results
differ depending on the metabolites to be detected, e.g., using perchloric acid
(PCA) as extraction solution was proven to have introduced more than 20% lost
to the metabolites in TCA cycle and no Glc was detected due to the solvent used,
while the loss in nucleiotides and amino acids was less than 5%. Thus, the choice
of quenching and extraction solution should be based on the target metabolites.
Rabinowitz and Kimball [100] performed a metabolome extraction study for
E. coli. Instead of quenching, centrifugation, at room temperature for 4 min
at 5000 g and filtration were used. 11 different extraction solution were com-
pared, namely MeOH/H2O (4:1), chloroform/MeOH (2:1), ethyl acetate, acidic
MeOH/H2O (4:1), basic MeOH/H2O (4:1), acidic ACN/MeOH/H2O (2:2:1), ba-
sic ACN/MeOH/H2O (2:2:1), ACN/MeOH/H2O (2:2:1), acidic ACN/H2O (4:1),
basic ACN/H2O (4:1) and ACN/H2O (4:1). Mixtures of acidic (0.1 M formic
acid-containing) ACN/water (4:1) and ACN/MeOH/H2O (2:2:1) has shown giving
the highest triphosphate yield.
Volmer et al. [101] evaluated sampling techniques for suspended animal cells
using CHO cells. Three different sampling techniques, namely fast filtration,
microstructure heat exchanger and centrifugation without prior quenching, were
compared. 85% pv{vq aqueous methanol at ´20 ˝C was used as the extraction
solution. ATP and Lac were both analysed by assay kits, amino acids by HPLC,
and other metabolites by hydrophilic interaction liquid chromatography-mass
54
2.4 Metabolomics analysis
spectrometry (HILIC/MS), and gas chromatography-mass spectrometry (GC/MS).
Sampling by fast filtration was shown to be preferable than using microstructure
heat exchanger and centrifugation without prior quenching.
Bu¨scher et al. [97] compared 6 methods, i.e., one separation technique, of gas
chromatography (GC), liquid chromatography (LC), or capillary electrophoresis
(CE), followed by one MS detection, namely time-of-flight mass spectrometry
(TOF-MS) or tandem mass spectrometry (MS/MS), by analyzing standard mixture
of 91 metabolites and 13C-labelled yeast extracts. The study showed that only
LC could handle large polar metabolites and thus LC and LC/GC was the best
separation techniques for metabolite analysis and 13C-labelling was mandatory for
quantitative measurements. In another study, Bu¨scher et al. [102] presented an ultra
high performance liquid chromatography-tandem mass spectrometry (UHPLC-
MS/MS) method by analysing 138 compounds covering central metabolism in 6
different cell-lines. The method was recommended by the authors for more than
half of all tested compounds were detected and quantified.
Motta et al. [103] monitored 15N-labelled living cell metabolism by 2D NMR
spectroscopy, where MeOH/chloroform compound in sonication procedure [104]
was used for metabolite extraction. A high-quality 2D correlation spectra of
metabolites directly from living cells was presented, which was believed to be the
first reported one. The short handing time (within 10-15 s) ensured the reliability
of the snapshot of cell metabolism.
2.4.3 Discussions
The quenching and extraction solutions were chosen based on the comparison
study by Dietmair et al., [96]. These were cold isotonic saline (0.9% NaCl, 0.5 ˝C)
for quenching and 50% aqueous ACN for extraction. Rather than fast filtration,
centrifugation was selected for cell/media seperation, as instructed by Sellick et
al. [95], which was easier to handle based on the author’s own attempts.
The metabolomic analysis conducted in this project aimed to analyse the
metabolites in glycolysis and the PPP, which are not large polar molecules. Thus,
GC is preferred in this study for separation. Additionally, as the study did not
require information on the molecular structure of the metabolites but only their
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identification, MS is the suitable technique. Hence, GC/MS was chosen.
2.5 Conclusions
Based on the review of previous studies, kinetic modelling is the best modelling
approach to analyse the intracellular behavior, while Monod kinetics could be
used to describe cell growth and death. Transport of metabolites through the cell
membrane can be used to link the intracellular and extracellular environments.
Due to the lack of kinetic data for modelling, metabolomic analysis is required.
The protocol for metabolomic analysis will be based on the protocol presented by
Sellick et al., [95] but the quenching and extraction steps are based on the protocol
suggested by Dietmair et al.. [96] Rather than LC/MS, GC/MS is used as Sellick
et al., [95] since GC is more suitable for the detection of non-polar molecules, while
LC is better suited for polar molecules. [105]
Regarding the GSA study of the constructed model, DGSM will be employed
based on the same code in MATLAB (MathWorks, U.K.) as in [83].
56
Chapter 3
Model Development
This chapter presents a novel kinetic modelling of CHO cell culture, which
includes detailed kinetic modelling of intracellular cytosolic glucose metabolism
and extracellular information, coupling by transmembrane transport. It is more
than a SCM that it includes extracellular information. Unlike the previous
models [34,67] that included two models, it is combined as one single model.
3.1 Model topology
The whole model for cytosolic glucose metabolism consists of two parts, namely a
cell growth model and a single cell model. The single cell model describes glucose
metabolism in the cytosol, while the cell growth model connects the single cell
model to the extracellular data and cell culture behavior.
Central Glc metabolism includes glycolysis, the pentose-phosphate pathway
and the TCA cycle. In Wu et al.’s work, [33] two organelles nucleus and lysosome
were considered. In Sanderson’s and Sidoli’s models, [34,67] an inspiring method
of modularization of the single cell model was introduced, the mitochondria
were treated as a separate compartment and trans-membrane transport for some
metabolites was considered. The TCA cycle is treated separately as it takes place
in mitochondria while glycolysis and pentose-phosphate pathway takes place in
cytosol.
However, in Sanderson’s and Sidoli’s models, [34,67] the extracellular and in-
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tracellular models are seperated models. To couple them as one single model,
the author introduced the following topological compartmentalization into our
model, as in Figure 3.1. The system is divided into 4 interlinked compartments,
which are the environment, media, cytosol, and mitochondria. The transport
between the environment and media are the inlet and outlet of the reactor. The
transport between media and cytosol, and between cytosol and mitochondria are
trans-membrane transport. All these four compartments are treated as well-mixed
and thus homogeneous.
Environment
Reactor Cell
Cytosol Mitochondria
Cell membrane Mitochondria membrane
Media
: Transport
Figure 3.1: Topological model compartmentalization
Detailed explainations for each compartment are as follows:
Environment is defined by the culture parameters set by the researcher, such
as [CO2], temperature, pH value, etc.
Media is the culture media, which is includes extracellular nutrient and metabolic
products. The extracellular metabolite concentrations of metabolite i is
denoted as [i]ex. The transport between media and cytosol is the transmem-
brane transport for the nutrients and products, e.g. glucose, lactate, amino
acids, etc..
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Cytosol is the site where most of the intracellular reactions considered in the
model take place and most of the intracellular metabolites and enzymes are
localised. The cytosol compartment is assumed to behave as a continuous
stirred tank reactor. The intracellular metabolite concentrations of metabo-
lite i is denoted as [i]. The interaction between the media and the cytosol
is defined by transmembrane transport, which is also responsible for the
link between the cytocol and the mitochondria, i.e. transport of pyruvate,
amino acids, etc..
Mitochrondria is the site for the TCA cycle, and the reactions in this compart-
ment are facilitated by membrane-bound enzymes.
Hence, intracellular glucose metabolism is divided into two different stages:
cytosolic stage, which includes glycolysis and pentose-phosphate pathway (PPP),
and mitochondrial stage, i.e., the TCA cycle. However, one should note that some
reactions belonging to the TCA cycle not only take place in the mitochondria but
also in the cytosol. [106]
3.2 Cell growth and death
The balance for cell growth and death is described as:
dXv
dt
“ pµ´ µdqXv, (3.1)
where µ is specific growth rate while µd is specific death rate. Cell death is mainly
caused by the accumulation of ammonia in the supernatant, thus the specific cell
death rate µd is
µd “ µd,max
`
KAmmexµd,m
˘nAmmexµd`
KAmmexµd,m
˘nAmmexµd ` prAmmsexqnAmmexµd , (3.2)
where µmax and µd,max are the maximum specific growth/death rate, K
Glcex
µ,m , and
KAmmexµd,m are Monod constants, K
Lacex
µ,i is dissociation constant and n
Ammex
µd
is hill
coefficient.
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In batch culture, no inlet or outlet flux rates are considered. Thus the mass
balance for extracellular glucose is
d rGlcsex
dt
“ qGlcXv (3.3)
where qGlc is the specific glucose uptake rate
qGlc “ Vt,Glc,maxprGlcsex ´ rGlcsqprGlcsex ´ rGlcsq `KGlct,Glc,m
, (3.4)
where Vt,Glc,max is the maximum specific transport rate, and K
Glc
t,Glc,m is the
Michaelis-Menten constant for glucose transport.
As the GS-CHO cell line NULL 8 was used, an assumption could be made that
all energy that glucose degradation produced is used for cell growth, for there is
no glutamine in CD-CHO media and the NULL 8 cell line does not produce a
recombinant product. Thus the calculation method for specific growth rate is:
µ “ `YATP{Glc ¨ qGlc ´ YATP{Lac ¨ qLac˘YX{ATP (3.5)
where YX{ATP is the yield of cells per ATP equal energy, YATP{Glc and YATP{Lac are
the yield of energy if glucose/Lac are fully degraded through the TCA cycle and
converted to ATP. The value of qLac can be either positive or negtive, denoting
the production and comsumtion of Lac, respectively.
For extracellular Lac, the accumulation/consumption is caused by the trans-
membrane transport. The mass balance for extracellular Lac is
d rLacsex
dt
“ qLacXv, (3.6)
where the specific Lac accumulation rate qLac is formed based on Michaelis-Menten
kinetics:
qLac “ Vt,Lac,maxrLacsrLacs `KLact,Lac,m
¨ rLacsex,max ´ rLacsexrLacsex,max
, (3.7)
where Vt,Lac,max is the maximum specific transport rates, K
Lac
t,Lac,m is Michaelis-
Menten constants for Lac transport, and rLacsex,max is assumed to be the maximum
extracellular Lac concentration.
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For extracellular ammonia, because Null 8 cell line does not produce antibodies,
the extracellular ammonia could directly link to the cell growth as:
qAmmex “ µYAmmex{XvXv, (3.8)
where YAmmex{Xv is the specific yield of of extracellular ammonia.
3.3 Cytosolic glucose metabolism
It is shown in literature [107] that the main metabolic fluxes of glucose metabolism
in the cytosol are in glycolysis, gluconeogenesis and the PPP, while fluxes exiting
glycolysis, gluconeogenesis and the PPP to other pathways are small. The largest
proportion of metabolic flux exiting glycolysis, gluconeogenesis and the PPP is
the flux towards nucleotide sugar donor metabolism, which is 3.55% of the whole
glucose uptake. Hence, the metabolic pathway for cytosolic glucose metabolism is
narrowed to glycolysis, gluconeogenesis and the PPP.
According to the genetic information from the Kyoto Encyclopedia of Genes
and Genomes (KEGG), a cytosolic glucose metabolic map for CHO cells based on
enzyme availability and expression were built. Since there are no data specifically
for CHO cells in KEGG, the closest species Rattus norvegicus was chosen instead.
As there are different enzymes existing in different species, the criteria of enzyme
existance are based on the relevant gene existance in Rattus norvegicus. If the
gene for an enzyme exist in KEGG for Rattus norvegicus, the enzyme is assumed
to be expressed in the cell and hence the reaction catalysed by the enzyme also
exists.
Unlike other pathways, the reaction kinetics for most of the enzymes in
glycolysis, gluconeogenesis and the PPP have been previously studied and reported.
For example, there can be more than 10 reactions between an amoni acid and
glycolysis, most of which have not been reported. Without sufficient reported
studies for the reaction kinetics of all the enzymes in the metabolic map, the
construction of a kinetic model is impossible. The enzyme kinetics were further
searched in BRENDA and published literature.
The main glucose metabolic pathway in cytosol is glycolysis, with about 40%
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glucose flux going through the PPP. [107,108] As there are some minor losses in
fluxes throughout glycolysis, gluconeogenesis and the PPP, [107] side reactions are
also included. The metabolic map built is shown in Figure 3.2. Each reaction
is named by the abbreviation of the enzyme that catalyses it. For the enzymes
that catalyse more than one reaction, namely Hexokinase (HK, EC 2.7.1.1),
Fructose-bisphosphate aldolase (Aldolase, ALD, EC 4.1.2.13) and Transketolase
(TK, EC 2.2.1.1) which catalyse 2 reactions each, reactions are indicated HK,
HK’, ALD, ALD’, TK and TK’. Energy carrier related metabolites, e.g., ATP,
ADP, AMP, NAD`, NADP, NADH`, NADPH, FAD, FADH2 and etc., and some
other metabolites, e.g., CO2, H2O and etc., are not shown in this map.
As has been discussed in Section 2.2, mass balance of metabolties can be
expressed similarly to Equation 2.8. However, one can see from Figure 3.1 that
transport also contribute to the metabolite concentrations. Furthermore, cell
growth dilutes the metabolic pools. However, the cell growth dilution rates are
much slower than reaction rates and transport rates. Therefore, general mass
balance equation Equation 2.8 can be adjusted for metabolite i as follows:
dci
dt
“ Fi,in ´ Fi,out `
mÿ
j“1
si,j ¨ rj, (3.9)
where Fin,i and Fout,i denotes metabolite i transport rate into and out of cytosol
of a single cell, respectively, which consider nutrient inlets, product/by-product
outlets and transport to the mitochondria. The cell growth model and intracellular
cytosolic glucose metabolism model are connected based on the transmembrane
transport of glucose and Lac as follows:
qGlc “ FGlc,inVcell, (3.10)
qLac “ FLac,outVcell, (3.11)
where cell volume
Vcell “ 4
3
pi
ˆ
dcell
2
˙3
and cell diameter dcell is equal to 15 µm.
[109]
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Figure 3.2: Metabolic map of cytosolic glucose catabolism in CHO cells
Based on the metabolic map built in Figure 3.2, enzymatic kinetic rates
were established as below, which were used to populate the mathematical model.
The enzymatic kinetics for each enzyme were searched seperatively in published
papers for closest species and condition. The expressions were condected based
on MichaelisMenten kinetics. The reported enzymatic kinetics are summarised
below:
Hexokinase
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Hexokinase (HK, EC 2.7.1.1) catalyses the conversion of glucose to Glucose
6-Phosphate (G6P), i.e., Glc`ATP Ñ G6P`ADP, and is strongly inhibited
by the product. There are 4 different isozymes of HK, of which HK IV
is also called Glucokinase (GCK, previous EC 2.7.1.2). Compared to HK
IV, HK I, II and III have low Km because of their high affinity for glucose.
Previous studies [68,110,111] suggested that the reaction follows an ordered
bi-bi mechanism. G6P is a noncompetitive inhibitor of glucose and ATP [110]
and the reaction rate can be written as
vHK “ VHK,max´
1` KGlcHK,mrGlcs
¯´
1` KATPHK,mrATPs
¯´
1` rG6Ps
KG6PHK,i
¯ . (3.12)
Glucose-6-phosphatase
Glucose-6-phosphatase (G6Pase, EC 3.1.3.9) catalyses the conversion of G6P
back to glucose, i.e., G6P` H2O Ñ Glc` Pi. Reaction follows a modified
Ping Pong bi-bi mechanism and glucose is the noncompetitive inhibitor. [112]
Therefore, the rate is:
vG6Pase “ VG6Pase,max´
1` KG6PG6Pase,mrG6Ps
¯´
1` rGlcs
KGlcG6Pase,i
¯ . (3.13)
Glucose-6-phosphate isomerase
Glucose-6-phosphate isomerase (GPI, EC 5.3.1.9) catalyses the conver-
sion of G6P into fructose 6-phosphate (F6P), i.e., G6P é F6P. Zalitis
and Oliver [113] showed that fructose 1-phosphate (F1P) and fructose 1,6-
bisphosphate (F16BP) were both competitive inhibitors of the forward
reaction and no clear inhibition of the reverse reaction was found. The
reaction rate follows
vGPI “ VGPI,max
1` KG6PGPI,mrG6Ps
´ V
1
GPI,max
1` KF6PGPI,mrF6Ps
ˆ
1` rF16BPs
KF16BP,F6PGPI,i
˙ . (3.14)
Phosphofructokinase-1
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Phosphofructokinase-1 (PFK1, EC 2.7.1.11) catalyses the important step
of glycolysis, the conversion of F6P and ATP to F16BP and ADP, i.e.,
F6P ` ATP Ñ F16BP ` ADP. Fructose 2,6-bisphosphate (F26BP) is
a potent activator for the enzyme by regulating the KF6PPFK1,m and n
F6P
PFK1
values. [114--116] The reaction rate follows
vPFK1 “ VPFK1,maxˆ
1`
´
KF6PPFK1,m
rF6Ps
¯nF6PPFK1˙´
1` KATPPFK1,mrATPs
¯ . (3.15)
Fructose 1,6-bisphosphatase
Fructose 1,6-bisphosphatase (FBP1, EC 3.1.3.11) catalyses the reaction of
from F16BP and H2O to F6P and phosphate (Pi), i.e., F16BP ` H2O Ñ
F6P` Pi. The reaction rate follows
vFBP1 “ VFBP1,max
1` KF16BPFBP1,mrF16BPs
. (3.16)
Fructose-bisphosphate aldolase
Fructose-bisphosphate aldolase (Aldolase, ALD, EC 4.1.2.13) catalyses the
reaction that breaks F16BP down into glyceraldehyde 3-phosphate (GA3P)
and dihydroxyacetone phosphate (DHAP), i.e., F16BP Ñ GA3P`DHAP.
The reaction rate follow
vALD “ VALD,max
1` KF16BPALD,mrF16BPs
´ V
1
ALD,max´
1` KGA3PALD,mrGA3Ps
¯´
1` KDHAPALD,mrDHAPs
¯ . (3.17)
Triose-phosphate isomerase
Triose-phosphate isomerase (TPI, EC 5.3.1.1) catalyses the reversible in-
terconversion of GA3P and DHAP, i.e., GA3P é DHAP. The inverse
reaction is competitively inhibits by PEP, 3PG, 2PG. [117,118] The reaction
65
3.3 Cytosolic glucose metabolism
rate follows
vTPI “ VTPI,max
1` KGA3PTPI,mrGA3Ps
´
1` rPEPs
KPEPTPI,i
¯´
1` r3PGs
K3PGTPI,i
¯´
1` r2PGs
K2PGTPI,i
¯
´ V
1
TPI,max
1` KDHAPTPI,mrDHAPs
´
1` rPEPs
KPEPTPI,i
¯´
1` r3PGs
K3PGTPI,i
¯´
1` r2PGs
K2PGTPI,i
¯ . (3.18)
Glyceraldehyde-3-phosphate dehydrogenase (phosphorylating)
Glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) (GAPDH,
EC 1.2.1.12) catalyses the reaction from GA3P into 1,3-bisphosphoglycerate
(13BPG), i.e., GA3P`NAD``Pi é 13BPG`NADH`H`. The reaction
rate follows
vGADPH “ VGADPH,max´
1` KGA3PGADPH,mrGA3Ps
¯ˆ
1` KNAD
`
GADPH,m
rNAD`s
˙ˆ
1` K
Pi
GADPH,m
rPis
˙
´ VGADPH,max´
1` K13BPGGADPH,mr13BPGs
¯´
1` KNADHGADPH,mrNADHs
¯ . (3.19)
Phosphoglycerate kinase
Phosphoglycerate kinase (PGK, EC 2.7.2.3) catalyses the reaction that trans-
fers a phosphate group from 13BPG to ADP, forming 3-phosphoglycerate
(3PG) and ATP, i.e., 13BPG ` ADP é 3PG ` ATP. The reaction rate
follows
vPGK “ VPGK,max´
1` K13BPGPGK,mr13BPGs
¯´
1` KADPPGK,mrADPs
¯ ´ V 1PGK,max´
1` K3PGPGK,mr3PGs
¯´
1` KATPPGK,mrATPs
¯ .
(3.20)
Bisphosphoglycerate mutase
Bisphosphoglycerate mutase (BPGM, EC 5.4.2.4) catalyses the reaction
from 13BPG into 2,3-bisphosphoglycerate (23BPG), i.e., 13BPG Ñ 23BPG.
Based on the reaction mechanism scheme developed by Mulquiney et al. [119],
the exact reaction of BPGM is 13BPG ` 3PG Ñ 23BPG ` 3PG and
13BPG ` 2PG Ñ 23BPG ` 3PG. However, K2PGBPGM,m is much larger than
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K3PGBPGM,m,
[119,120] so reaction 13BPG` 3PG Ñ 23BPG` 3PG is considered
instead. The reaction rate follows
vBPGM “ VBPGM,max´
1` K13BPGBPGM,mr13BPGs
¯´
1` K3PGBPGM,mr3PGs
¯ . (3.21)
Bisphosphoglycerate phosphatase
Bisphosphoglycerate phosphatase (BPGP, EC 3.1.3.13) catalyses the reaction
from 23BPG into 3PG, i.e., 23BPG` H2O Ñ 3PG` Pi. The reaction rate
follows
vBPGP “ VBPGP,max
1` K23BPGBPGP,mr23BPGs
. (3.22)
Phosphoglycerate mutase
Phosphoglycerate mutase (PGM, EC 5.4.2.1) catalyses the conversion of
3PG to 2PG through a 2,3-bisphosphoglycerate (23BPG) intermediate, i.e.,
3PG` rm23BPGé 2PG` 23BPG. The reaction rate follows
vPGM “ VPGM,max´
1` K3PGPGM,mr3PGs
¯´
1` K23BPGPGM,mr23BPGs
¯ ´ V 1PGM,max´
1` K2PGPGM,mr2PGs
¯´
1` K23BPGPGM,mr23BPGs
¯ .
(3.23)
Phosphopyruvate hydratase
Phosphopyruvate hydratase (enolase, ENO, EC 4.2.1.11) catalyses the
conversion of 2PG into phosphoenolpyruvate (PEP), i.e., 2PG é PEP`H2O.
The reaction rate follows
vENO “ VENO,max
1` K2PGENO,mr2PGs
´ V
1
ENO,max
1` KPEPENO,mrPEPs
. (3.24)
Pyruvate kinase
Pyruvate kinase (PK, EC 2.7.1.40) catalyses the reaction that transfers a
phosphate group from PEP to ADP, forming one molecule of Pyr and one
molecule of ATP, i.e., PEP`ADP Ñ Pyr`ATP. The reaction rate follows
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vPK “ VPK,max´
1` KPEPPK,mrPEPs
¯´
1` KADPPK,mrADPs
¯ ´ V 1PK,max
1` K
Pyr
PK,m
rPyrs
. (3.25)
Lactate dehydrogenase
Lactate dehydrogenase (LDH, EC 1.1.1.27) catalyses the reversible con-
version from pyruvate, the final product of glycolysis, to Lac, i.e., Pyr `
NADH` H` é Lac` NAD`. The reaction rate follows
vLDH “ VLDH,maxˆ
1` K
Pyr
LDH,m
rPyrs
˙´
1` KNADHLDH,mrNADHs
¯´ V 1LDH,max´
1` KLacLDH,mrLacs
¯´
1` KNADLDH,mrNADs
¯ . (3.26)
Pyruvate dehydrogenase
Pyruvate dehydrogenase (PDH, EC 1.2.4.1), the first enzyme of the pyruvate
dehydrogenase complex, catalyses the first reaction reaction from pyruvate
towards acetyl-CoA. The reaction rate follows
vPDH “ VPDH,max
1` K
Pyr
PDH,m
rPyrs
. (3.27)
Glucose-6-phosphate dehydrogenase
Glucose-6-phosphate dehydrogenase (G6PD, EC 1.1.1.49) catalyses the entry
reaction of the PPP, i.e.,the conversion of G6P into 6-phosphogluconolactone
(6PGL), i.e., G6P ` NADP` Ñ 6PGL ` NADPH ` H`. NADPH is the
competitive inhibitor of G6P. [121] The reaction rate follows
vG6PD “ VG6PD,max„
1` KG6PG6PD,mrG6Ps
ˆ
1` rNADPHs
KNADPH,G6PG6PD,i
˙ˆ
1` KNADP
`
G6PD,m
rNADP`s
˙ . (3.28)
6-Phosphogluconolactonase
6-Phosphogluconolactonase (PGL, EC 3.1.1.31) catalyses the reaction that
converts 6PGL to 6-phosphogluconate (6PG), i.e., 6PGL ` H2O Ñ 6PG.
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The reaction rate follows
vPGL “ VPGL,max
1` K6PGLPGL,mr6PGLs
. (3.29)
Phosphogluconate dehydrogenase (decarboxylating)
Phosphogluconate dehydrogenase (decarboxylating) (PGD, EC 1.1.1.44)
catalyses the conversion of 6PG into ribulose 5-phosphate (Ru5P), i.e.,
6PG`NADP` Ñ Ru5P`NADPH`H2O`H`. NADPH is the competitive
inhibitor of NADP`. [122] The reaction rate follows
vPGD “ VPGD,max´
1` K6PGPGD,mr6PGs
¯„
1` KNADP
`
PGD,m
rNADP`s
ˆ
1` rNADPHs
KNADPH,NADP
`
PGD,i
˙ . (3.30)
Ribulose-phosphate 3-epimerase
Ribulose-phosphate 3-epimerase (pentose-5-phosphate 3-epimerase, PPE, EC
5.1.3.1) catalyses the reaction that converts Ru5P into xylulose 5-phosphate
(X5P), i.e., Ru5P é X5P. The reaction rate follows
vPPE “ VPPE,max
1` KRu5PPPE,mrRu5Ps
´ V
1
PPE,max
1` KX5PPPE,mrX5Ps
. (3.31)
Ribose-5-phosphate isomerase
Ribose-5-phosphate isomerase (RPI, EC 5.3.1.6) catalyses the conversion
between Ru5P and ribose-5-phosphate (R5P), i.e., Ru5P é R5P. The
reaction rate follows
vRPI “ VRPI,max
1` KRu5PPRI,mrRu5Ps
´ V
1
RPI,max
1` KR5PPRI,mrR5Ps
. (3.32)
Transketolase
Transketolase (TK, EC 2.2.1.1) catalyses 2 different reversible reactions that
transfer 2-carbon fragment from X5P to (1) R5P, generating sedoheptulose
7-phosphate (S7P) and GA3P, i.e., X5P`R5P é GA3P` S7P, and (2) to
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erythrose-4-phosphate (E4P), generating F6P and GA3P, i.e., X5P`E4P é
GA3P` F6P. The reactions rate follow
vTK “ VTK,max´
1` KX5PTK,mrX5Ps
¯´
1` KR5PTK,mrR5Ps
¯ ´ V 1TK,max´
1` KGA3PTK,mrGA3Ps
¯´
1` KS7PTK,mrS7Ps
¯ , (3.33)
vTK1 “ VTK1,max´
1` KX5PTK,mrX5Ps
¯´
1` KE4PTK,mrE4Ps
¯ ´ V 1TK1,max´
1` KGA3PTK,mrGA3Ps
¯´
1` KF6PTK,mrF6Ps
¯ . (3.34)
Transaldolase
Transaldolase (TA, EC 2.2.1.2) catalyses the reaction that transfer 3-carbon
fragment from S7P to GA3P, generating E4P and F6P, i.e., S7P`GA3P é
E4P` F6P
vTA “ VTA,max´
1` KS7PTA,mrS7Ps
¯´
1` KGA3PTA,mrGA3Ps
¯ ´ V 1TA,max´
1` KE4PTA,mrE4Ps
¯´
1` KF6PTA,mrF6Ps
¯ . (3.35)
3.4 Conclusions
The enzyme studies cited above for reaction kinetic mechanisms were achieved
independently for each enzyme. It is generally acceptable to use the Km and Ki
values from this literature but not the Vmax values. The attempt of kinetically
describing and dynamically simulating all the reactions involved in glycolysis,
gluconeogenesis and the PPP has not been published before for mammalian
cells. However, modelling studies based solely on data for Km and Ki values
are not possible. The model needs to be parameterized for Vmax values and
other missing parameter values which has not been reported for the experimental
system described by the model. Hence, metabolomic analysis is needed for the
parameterization.
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Chapter 4
Experimental Materials and
Methods
This chapter presents the methodology for the experimental work the results
of which were used to parameterize the mathematical model. As discussed in
Chapter 3, certain parameter values found in the literature are either insufficient
or unsuitable for model development and therefore need to be estimated from
in-house experimental data. This chapter describes the methods employed for cell
culture, sample handling, extracellular and intracellular metabolite analysis.
4.1 Cell culture
The GS-CHO cell-line Null 8 (Lonza Biologics plc., U.K.) was employed in this
study. The cells were washed and recovered in CD-CHO medium (Gibco, Life
Technologies, U.K.) supplemented with 25 µM methionine sulfoximine (MSX,
Sigma-Aldrich, U.K.), at a seeding concentration of 0.3ˆ106 viable cells{mL, in a
suitably sized Erlenmeyer flask (Corning, U.K.). Batch cultures were maintained
in an incubator at 37 ˝C, a humidified atmosphere of 8% CO2, on an orbital
shaker rotating at 140 rpm. Cells were subcultured on day 3 after revival and
on day 4 for all subsequent subcultures, for which a seeding concentration of
0.2ˆ 106 viable cells{mL was used.
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4.2 Glc-13C6 labelled cell culture
The cells were subcultured in Glc-free CD-CHO media (Gibco, Life Technologies,
U.K.) supplemented with 25 µM MSX and 3 g{L Glc (Sigma-Aldrich, U.K.) in a
culture volume of 200 mL. Another 1.5 g uniformly labelled Glc-13C6 (CortecNet,
France) dissolved in 70 mL fresh Glc-free CD-CHO media was added to the
culture at day 3.
4.3 Sampling
Cultures were sampled twice per day during day 3 to day 6 (day 3 to day 9 for
carbon labelled experiment), and once per day during other days. Cell count was
determined using the trypan blue (Life Technologies, U.K.) dye exclusion method
using light microscopy (Leica, U.K.). 1.5 mL culture samples were removed,
centrifuged at 100 g for 5 min and the supernatant collected as extracellular
samples and frozen at ´20 ˝C until further analysis.
Cell culture samples containing 1ˆ 107 cells (sample volume determined by
viable cell concentration) were removed and quenched by using 5 times sample
volume of quenching solution (ice-cold 0.9% pw{vq sodium chloride (NaCl, Sigma-
Aldrich, U.K.) in Milli-Q water) and washed. Quenched samples were then
resuspended in 2 mL of extraction solution (ice-cold 50% acetonitrile in Milli-Q
water), incubated on ice for 10 min and spun down at 18000 g for 5 min. The
supernatant was collected and the remaining were then frozen at ´80 ˝C until
further analysis.
4.4 Metabolomic analysis
Bioprofiler analysis
For experiment using unlabelled Glc, the extracellular samples were thawed
and analysed using a BioProfile Automated Analyzer 400 (Nova Biomedical,
U.K.), which uses enzyme/amperometric method for the analysis of Glc,
Lac, Gln, Glu, and ion selective electrode method for the analysis of NH4`,
Na` and K`.
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GC/MS analysis
For the experiment using carbon-labelled Glc, GC/MS was performed to
analyse the intracellular and extracellular metabolites.
1. Metabolite standards: Since most metabolites we were interested in
were not in the MS library, in order to make a correct detection,
metabolite solutions were made as standards to build our own library.
Besides D-Glc-13C6 (CortecNet, France), all other standards are from
Sigma-Aldrich, U.K. with highest purity available. A detailed list of
the metabolite used to build out own library is presented in Table B.1.
2. Derivatization: Samples were transferred into a 2 mL glass Agilent vial
(Agilent Technologies, U.K.), supplemented with 10 µL of myristic-d27
acid (Sigma-Aldrich, U.K.) solution (2 mM in water/methanol/iso-
propanol (2:5:2)) and thoroughly dried using a SpeedVac (Eppen-
dorf, U.K.) with vacuum overnight. Dried samples were resuspended
in 10 µL methoxyamine hydrochloride (Sigma-Aldrich, U.K.) solu-
tion (40 mg{mL in anhydrous pyridine (VWR, U.K.)), incubated at
30 ˝C for 90 min, and then supplemented with 30 µL of N-methy-
N-(trimethylsilyl) trifluoroacetamide with 1% trimethylchlorosilane
(MSTFA + 1% TMCS, Sigma Aldrich, U.K.), and incubated at 37 ˝C
for 30 min. 10 µL internal standard (2 mM 2-fluorobiphenyl (Fluo-
rochem, U.K.) in anhydrous pyridine) was then added.
3. GC/MS analysis: GS/MS analysis was performed on HP 6890 series
GC system and HP 5793 Mass select Detector (Hewlett-Packard, U.S.)
using MSD ChemStation software. Components were separated by
chromatography on a HP5MS column using 1.2 mL{min helium as
carrier gas. The inlet was held at 250 ˝C, samples (1 µl) were introduced
either by pulsed split (1 : 10) or pulsed splitless injections. For split
injections the GC was programmed to hold at 60 ˝C for 1 min, then
the temperature steadily increased to 325 ˝C at a rate of 10 ˝C{min
and held for 10 min; splitless injections followed the same temperature
profile but started at 50 ˝C.
The mass spectrometry results were then identified using Wiely 275
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library and Mass Bank online mass spectrometry database (http:
//www.massbank.jp/). A library for metabolites was built using MS
results of the standards, shown in Appendix B.
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Chapter 5
Experimental Results
This chapter presents the experimental results, including cell growth, intracel-
lular/extracellular metabolomic analysis generated by bioprofiler and GC/MS
experiments. Two sets of experimental results are shown, which are (1) batch
cultue with unlabelled glucose under 5% CO2 and (2) fed-batch culture with
labelled glucose under 8% CO2.
5.1 Cell growth results
The cell growth curve for viable cell concentrations are presented in 5.1. It is clear
that in the growth curve of the labelled experiment, there is a clear decreasing
step which represents the feed of Glc-13C rich media. The cell growth results are
used for parameter estimation in Chapter chap:modelresult.
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Figure 5.1: Viable cell concentration of GS-CHO cells in CD-CHO media in
unlabelled (5% CO2) and labelled (8% CO2) experiments
5.2 Bioprofiler analysis results
Samples of the unlabelled experiment were analysed using bioprofile analyzer. As
the samples of unlabelled experiment had been frozen, the bioprofile analyzer
experiment results of pH, pO2, pCO2,
“
HCO´3
‰
were not reliable. The results of
four metabolites and two ions are presented in Figure 5.2. The CD-CHO media
used was glutamine-free, and the analysis results also confirmed that no glutamine
was presented in the media throughout the whole cell culture process.
The main nutrient, glucose, was consumed fast while by-products lactate
and ammonia accumulated. However, only about a quarter of glutamate was
consumed. The Na` concentration changed only slightly while K` decreased as
cell concentration increased, which suggested that K` ions entered the cells and
then released back to the media after cell death.
The bioprofiler results are used later in Chapter 6 for parameter estimation.
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Figure 5.2: Bioprofiler analysis results of GS-CHO cells in CD-CHO media in
unlabelled (5% CO2) experiment of extracellular (a) Glu, (b) Glc, (c) Lac, (d)
Amm, (e) Na`, and (f) K`
5.3 GC/MS analysis results
The samples of the labelled experiment were analysed using GC/MS. GC/MS
analysis with 1:10 split ratio injection was performed first and a typical GC result
was shown as Figure 5.3(a). For the metabolite standards used (see Table B.1),
most of the standards could be identified except 23BPG, F16BP and G16BP,
which all have two phosphate groups. However, among the metabolites that
have been identified using standards, only Glc, Lac and Glyc3P were present in
quantifiable levels in the cell extract samples. The retention time generated from
the metabolite standards were used to identify the peaks in the real samples.
Hence, splitless injection analysis was performed with double/triple sampling
volume (2 ˆ 107 and 3 ˆ 107 cells, respectively) and the washing step in the
sampling procedure was omitted (see Section 4.3). No splitless analysis for
metabolite standards was performed as they had already been identified using
split injection. As shown in Figure 5.3(b), the splitless experiment results showed
many more and bigger peaks. However, out of the metabolites in the metabolic
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map (Figure 3.2), no more metabolites were identified than using the split injection.
The reasons why the split and spliteless experiments show many differences are:
• Higher sampling amount in splitless experiment. 2-3 times more cells were
used which resulted in double/triple peak areas.
• Samples were diluted in split injection. Switching the 1:10 split injection to
splitless will make peak areas 10 times bigger.
• Washing step was omitted. Washing step is crucial for the metabolites that
exist both intracellularly and extracellularly, i.e., glucose, lactate, some
amino acids, etc. However, for the metabolites that only exist intracellularly,
the washing step is unnecessary and also extends the sampling time.
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Figure 5.3: Comparison of typical GC results using (a) split and (b) spliteless
injections
Based on the results of metabolite standards, Wiely 275 library and Mass Bank
online mass spectrometry database (http://www.massbank.jp/), the GC/MS
results were analysed with focus on metabolites of glucose metabolism and amino
acids. The retention time of metabolites and internal standards in GC/MS analysis
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described in Section 4.4 were summarized in Table B.1. And Table B.1 also shows
detectability of metabolites and internal standards in the experiment. A library
for mass spectrometry was created as shown in Appendix B.
As retention times generated using same experiment protocol remain the same
for the same molecule in different experiments. This information is useful as an
index and a starting point of peak identification in GC/MS results.
The results of the split injection analysis are summarized in Figures 5.4 and
5.6. However, as some peaks of metabolites in the GC/MS result were not big
enough to be quantified, Figures 5.5 shows the metabolites using the peak heights
(noise omitted). For the same compounds, the GC peak shapes are similar. Thus,
to some extent, the dynamic peak height of a compound qualitatively shows its
dynamic behaviour, i.e., consumption/accumulation rate.
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Figure 5.4: Metabolite concentrations of extracellular (a) Glc, (b) Lac, (c) Leu/Ile,
(d) Ser (e) Thr and (f) Val of GS-CHO cells in CD-CHO media in labelled (8%
CO2 in GC/MS experiment
As shown in Figures 5.4 to5.6, besides glucose and lactate, amino acids were
the main metabolites detected. MS is not capable of distinguishing between Leu
and Ile, because they are isomers. The results show various extracellular amino
acids such as Leucine (Leu)/Isoleucine (Ile), Serine (Ser), Thronine (Thr), Valine
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Figure 5.5: Peak height of extracellular (a)Asp, (b) Gly, (c) Met, (d) Pro, (e)
Phe and intracellular (f) Fum of GS-CHO cells in CD-CHO media in labelled (8%
CO2 in GC/MS experiment
(Val), Asparatate (Asp), Methonine (Met) and Phenyalanine (Phe) all decrease
and act as input to cell growth. While other amino acids namely Glycine (Gly)
increase significantly as well as Proline (Pro) increased slightly. Val is directly
linked to Pyr in glycolysis, while Ser is directly linked to 3PG in glycolysis. Whilst,
Phe is linked to E4P in the PPP and PEP in glycolysis. Pro is linked to glutamate,
Leu and Ile arre linked to Pyr in glycolysis and Succinyl CoA in the TCA cycle.
Furthermore, intracellular Fum and Glyc3P were also detected.
However, unlike the bioprofiler results, extracellular glutamate was not detected
in either analysis with split and splitless injections. Furthermore, although
intracellular glutamate was detected in GC/MS experiment, it was not detected
in all samples.
As the first GC/MS analysis using extracts from 1ˆ 107 with split injection
had not provided good detection on the glycolytic intermediates we required to
validate our model. We tried to increase the number of cells, omit the washing
step and looked at splitless injection, we were unable to dectect the glycolytic
intermediates we required to validate our model. However, we gained valuable
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Figure 5.6: Metabolite concentrations of intracellular (a) Ala, (b) Fru, (c) Glc, (d)
Gly (e) Gly3P, (f) Lac, (g) Leu/Ile, (h) Mal, (i) Pro, (j) Ser, (k) Thr and (l) Val
of GS-CHO cells in CD-CHO media in labelled (8% CO2 in GC/MS experiment
information on other metabolites, primarily amino acids, which can help inform
other studies into CHO cell metabolism.
The experimental results for intracellular and extracellular Glc and Lac shown
in Figures 5.4(a)(b) and 5.6(c)(e) are used for parameter estimation in Chapter 6.
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5.4 Conclusions
The cell growth curve and the concentrations of the extracellular metabolites
(glucose and lactate) are used as the macroscopic level data for parameter estima-
tion of the cell growth and death rates, while the concentrations of intracellular
metabolites are used as microscopic level data for the estimation of parameters
pertaining to cell metabolism. Intracellular and extracellular glucose and lactate
concentrations are also used for the estimation of parameters associated with the
transport of these molecules into and out of the cell.
The results for amino acid levels were not used for model development or
parameterisation, since the current model does not consider amino acid metabolism.
They do, however, provide useful insight to GS-CHO cell metabolism and can aid
future modelling efforts.
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Chapter 6
Parameter Calculation,
Estimation and Model simulation
6.1 Overall strategy
The mathematical model for cell growth and cytosolic Glc metabolism presented
in Chapter 3 was simulated in gPROMS (Process Systems Enterprise ltd., U.K.).
The Braunschweig Enzyme Database (BRENDA) was used as initial search for
kinetic data. However, as for other models for biological process, several kinetic
parameters have not been determined experimentally or are not suitable as the
experiments in which they were measured were performed under different condition
than those occurring in a typical cell culture (e.g., different pH or temperature
than physiological conditions).
An overall parameter calculation/estimation strategy is presented in Figure
6.1. As the parameterisation was performed on the same model, the parameter
calculation and estimation affected each other. Hence, the parameterisation was
not finished until the criterion that the difference between simulated metabolic
fluxes and the metabolic fluxes used to calculate the Vmax values were less than 5%
was satisfied. 5% is chosen as it is generally considered as the limit of experimental
error. The finalised model was then used in Chapter 7 for sensitivity analysis and
model-based cell culture and metabolism studies.
The calculation/estimation algorithm might provide some results which are
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Figure 6.1: Overall strategy for modelling
not the best solution. And the calculation/estimation results would possibly be
local optimisation results rather than global ones. However, the results fit the
curves of all the dynamic experimental results which are considered in this system,
i.e., viable cell concentrations, intracellular Glc and Lac, extracellular Glc, Lac
and Amm. Furthermore, the simulation results of metabolic flux rates are quite
close to the assumptions (with less than 5% difference). The obtained parameter
values and the parameterized model would be a good one for the data obtained.
However, as the enzyme kinetics reported were estimated from in vitro ex-
periments, it is generally safe to used the Km values from literature, which are
summarized in Table 6.1, but not the Vmax values, because Km values only depend
on the environment, e.g. pH and temperature, but Vmax values depend not only on
the kcat but also the enzyme concentration rE0s, for which it is usually arbitrary
in in vitro experiments.
Due to insufficient information on parameter values in the relevant literature,
certain parameters require estimation. Hence, as shown in Chapter 4, experiments
were performed in order to parameterise the model. As CHO Null 8 cell line was
used, the energy generated in metabolism was used for cell growth only. Hence,
this model was focused on the exponential phase only, where the specific cell
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growth rates were high and the intracellular metabolism were quite stable.
Table 6.1: Parameter values in literature
Parameter Value Unit Ref. Parameter Value Unit Ref.
KGlcHK,m 0.11 mM 110 kPGM,cat 795 s
´1 119
KATPHK,m 0.8 mM 110 k
1
PGM,cat 714 s
´1 119
KG6PHK,i 9.1 mM 68 K
2PG
ENO,m 0.12 mM 123
KG6PG6Pase,m 1.8 mM 112 K
PEP
ENO,m 0.37 mM 123
KGlcG6Pase,i 115 mM 112 K
PEP
PK,m 0.07 mM 124
KG6PGPI,m 0.705 mM 113 K
ADP
PK,m 1.05 mM 124
KF6PGPI,m 0.12 mM 113 K
Pyr
PK,m 0.0204 mM 125
KF16BP,F6PGPI,i 7.55 mM 113 K
Pyr
LDH,m 0.03 mM 126
KF6PPFK1,m
˚ KLacLDH,m 1.79 mM 127
nF6PPFK1
˚ KNADHLDH,m 0.011 mM 128
KATPPFK1,m 0.06 mM 129 K
NAD
LDH,m 0.18 mM 128
KF16BPFBP1,m 0.0013 mM 130 K
Pyr
PDH,m 0.0204 mM 125
KF16BPALD,m 0.0519 mM 131 K
G6P
G6PD,m 0.329 mM 121
KGA3PALD,m 1 mM 132 K
NADP`
G6PD,m 0.1 mM 121
KDHAPALD,m 2 mM 132 K
NADPH,G6P
G6PD,i 0.01 mM 121
KGA3PTPI,m 0.32 mM 117 K
6PGL
PGL,m 0.08 mM 133
KDHAPTPI,m 0.62 mM 117 K
6PG
PGD,m 0.157 mM 122
KPEPTPI,i 0.5 mM 118 K
NADP`
PGD,m 0.258 mM 122
K3PGTPI,i 0.51 mM 118 K
NADPH,NADP`
PGD,i 0.021 mM 122
K2PGTPI,i 4.1 mM 118 K
Ru5P
PPE,m 0.19 mM 134
kTPI,cat 5.1ˆ 105 min´1 118 KX5PPPE,m 0.5 mM 135
k1TPI,cat 5.2ˆ 104 min´1 118 KRu5PPRI,m 0.78 mM 136
KGA3PGADPH,m 0.149 mM 137 K
R5P
PRI,m 2.2 mM 136
KNAD
`
GADPH,m 0.071 mM 137 K
R5P
TK,m 0.33 mM 138
KPiGADPH,m 4 mM 137 K
X5P
TK,m 0.12 mM 138
continued on next page
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Table 6.1. continued from previous page
Parameter Value Unit Ref. Parameter Value Unit Ref.
K13BPGGADPH,m 0.032 mM 139 K
E4P
TK,m 0.36 mM 140
KNADHGADPH,m 0.02 mM 139 K
GA3P
TK,m 4.9 mM 140
K13BPGPGK,m 0.005 mM 141 K
F6P
TK,m 7 mM 140
KADPPGK,m 0.12 mM 141 K
S7P
TK,m 4 mM 142
K3PGPGK,m 0.1 mM 141 K
GA3P
TA,m 0.038 mM 143
KATPPGK,m 0.11 mM 141 K
E4P
TA,m 0.09 mM 143
K13BPGBPGM,m 0.0051 mM 119 K
S7P
TA,m 0.285 mM 143
K3PGBPGM,m 0.001 mM 119 K
F6P
TA,m 1.2 mM 143
K23BPGBPGP,m 0.049 mM 119 d 15 µm 109
K3PGPGM,m 0.17 mM 119 YATP{Glc 38 - 25--27
K2PGPGM,m 0.026 mM 119 YATP{Lac 18 - 25--27
K23BPGPGM,m 0.00015 mM 119
˚ See Section 7.3
6.2 Quasi-steady state parameter calculation
Quasi-steady state parameter calculation is based on the parameter values and
MFA results found in literature. As the intracellular metabolome analysis provided
insufficient dynamic intracellular metabolite concentrations, the quasi-steady state
assumption was made and metabolite concentrations stated in Table 6.2 were
used for metabolite concentrations in exponential phase (mid exponential phase
day 4 used), when all nutrients are used for cell growth and cell growth rate
is constant and nutrients are still in abundance and not limiting cell growth.
Adenine nucleotides (ATP, ADP and AMP), oxidized/reduced pyridine coenzymes
(NADP`, NADPH, NAD`, NADH) and some other metabolites were assumed
to be stable (see Table 6.2 for details). The concentrations of 13BPG, 23BPG
and 6PGL were assumed to be the same as the Km values in which they acted
as substrates, while the concentrations of NADH, NADP` and NADPH were
assumed to be the same as the concentration of NAD`.
Based on a MFA study for CHO cell culture in fed-batch bioreactor using 2D
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Table 6.2: Intracellular metabolite concentrations for CHO cells
Metabolite Conc. (mM) Ref. Metabolite Conc. (mM) Ref.
13BPG 0.005˚ 141 GA3P 0.021 144
23BPG 0.051˚ 119 Glc 2.377 145,146
2PGA 0.005 145,146 Lac 2.660„6.700 145,146
3PGA 0.040„0.048 145,146 NAD` 0.31: 145,146
6PG 0.018 68 NADH 0.003-0.005: 147
6PGL 0.080˚ 133 NADP` 0.005: 148
ADP 1.059: 145,146 NADPH 0.995: 148
ATP 3.075: 145,146 Pi 5.500: 145,146
DHAP 0.040-0.046 145,146 PEP 0.008 145,146
E4P 0.004 68 Pyr 0.056 145,146
F16BP 0.046 145,146 R5P 0.009 68
F26BP 0-0.070 149 Ru5P 0.012 68
F6P 0.362 145,146 S7P 0.068 68
G6P 1.033 145,146 X5P 0.018 68
˚ Assumed the concentration on day 4 is the same as Km
: Assumed to be constant
[13C, 1H] NMR spectroscopy, [107] metabolic fluxes of GS-CHO cells were calculated
for the exponential cell growth phase. The parameter calculation results were
shown in Table 6.3. For fluxes feeding out of the system, assumption was made
that the ratios between each outlet flux and its adjacent flux was constant.
The parameter calculation was performed in MATLAB. Vmax values were
calculated using the reaction rate expressions in Section 3.3, the parameter
values in Table 6.1. metabolite concentrations in Table 6.2 (assumed to be
the concentration on day 4), and metabolic flux rates in Figure 6.2 which were
obtained based on the assumptions that:
1. the percentage of metabolic flux rates towards the PPP and other pathways
were based on the reported the reported MFA study [107] and
2. as the reported fluxes were net fluxes only, the forward reaction rates were
assumed to be twice as the backward ones, unless:
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(a) There were reported correlation between the forward and the backward
reactions, i.e., kcat value from same experiments (TPI and PGM), or
(b) Simulation results excessed the reasonable ranges.
During the calculation and estimation for parameters, all metabolite con-
centrations should be closely monitored, as the intracellular metabolite
concentrations have only one assumption that the concentration on day 4
equal to the reported concentrations. However, in some cases, when Vmax
and Km values were relatively small, the simulation of certain metabolite
could be unreasonably high due to the accumulation. And in this case, the
Vmax value was considered to be too small.
Table 6.3: Calculated Vmax values
Parameter Value (mM{d) Parameter Value (mM{d)
VALD,max 5649 VPGL,max 1346
V 1ALD,max 2939 VPGM,max 62370
VBPGM,max 896 V
1
PGM,max 56015
VBPGP,max 849 VPK,max 110170
VENO,max 141850 V
1
PK,max 3870
V 1ENO,max 134040 VPPE,max 14893
VFBP1,max 1365 V
1
PPE,max 12730
VG6Pase,max 4466 VPRI,max 29196
VG6PD,max 36345 V
1
PRI,max 54288
VGAPDH,max 98498 VTA,max 6452
V 1GAPDH,max 162586 V 1TA,max 3102
VGPI,max 3010 VTK,max 127750
V 1GPI,max 1428 V 1TK,max 3100700
VHK,max 4772 VTK1,max 334061
VPFK1,max 7710 V
1
TK1,max 105410
VPGD,max 16231644 VTPI,max 21524
VPGK,max 10706 V
1
TPI,max 2196
V 1PGK,max 8716
Based on the calculated Vmax values, maximum reaction rates during the
earlier stage of glycolysis, i.e., Vmax values of HK, G6Pase, GPI, PFK1, FBP1,
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Figure 6.2: Metabolic flux distribution for exponential phase in CHO cells
ALD and TPI, are much smaller than those for the later stages, i.e., GADPH,
PGK, PGM, ENO and PK, with only two exception, BPGM and BPGP in a
branch of glycolysis, which suggested that the rate limiting steps of glycolysis
were the earlier reactions up to GA3P. The big increase of the Vmax values before
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and after GA3P in glycolysis has made the reaction GAPDH a bottleneck of the
metabolism, which has beed reported to be a bottleneck in S. cerevisiae cells. [150]
For the PPP, only the Vmax values of G6PD and TA were much smaller than the
others, which implied that the inlet and outlet of the PPP were the limitation of
that branch of cytosolic Glc metabolism.
6.3 Dynamic parameter estimation
Parameter estimation based on dynamic experimental results was performed using
the ‘parameter estimation’ entity in gPROMS based on a SRQPD sequential
quadratic programming code. Dynamic experimental results, including extracellu-
lar Glc, Amm and Lac, intracellular Glc, Lac, and viable cell concentrations, were
used for parameter estimation. Two sets of experiment data were used for pa-
rameter estimation and thus generated two sets of estimation results. Estimation
results were shown in Table 6.4, in which the unlabelled and labelled experiments
were described in Section 4.1, and briefly:
Unlabelled: under 5% CO2 using CD-CHO media,
Labelled: under 8 % CO2 using Glc-free CD-CHO with 3 g{L Glc and additional
6 g{L U-13C-Glc was fed on day 3, precisely day 3.09 in the actual experiment.
µd,max for the unlabelled experiment is about 4 times higher than the one used
for the labelled experiment, which suggests that the CO2 concentration is linked
to the Lac concentration which affected the cell death rate. As CO2 acts as a pH
buffer in the incubator, a difference in the pH value would alter the cell growth
rate indirectly by altering the Glc and Lac transport. This would also alter the
cell death rate directly by altering the maximum specific cell death rate.
As shown in Table 6.4, some parameter values for both experiments were the
same, which suggests that they are pH-independent. For example, the two yield
constants YAmmex{Xv and YX{ATP only depend on the intracellular metabolism.
However, some parameters are different. This may be due to the experiments,
where the parameter values differ from each other as a result of the different
CO2 conditions. Under different CO2 concentrations, the pH value of the culture
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Table 6.4: Estimated parameter values
Estimated Parameter Value
Parameter Unlabelled expriment Labelled expriment Unit
µd,max 14.68 3.66 1{d
KAmmexµd,m 31.67 31.67 mM
KGlct,Glc,m 243.00 243.00 mM
rLacsex,max 35.91 9.73 mM
KLact,Lac,m 121.88 196.23 mM
nAmmexµd 2.00 2.00 ´
VLDH,max 16196.94 1010.59 mM{d
V 1LDH,max 1619.70 101.06 mM{d
VPDH,max 1787.38 1869.12 mM{d
Vt,Glc,max 3.00ˆ 10´8 1.39ˆ 10´8 mmol{cell¨d
Vt,Lac,max 1.75ˆ 10´7 3.97ˆ 10´8 mmol{cell¨d
YAmmex{Xv 9.41ˆ 10´10 9.42ˆ 10´10 mmol{cell
YX{ATP 9.70ˆ 106 9.70ˆ 106 mmol{cell
changes. This changes the saturation concentration of Lac, as Lac presents as
lactic acid. µd,max for the unlabelled experiment is much bigger than the labelled
experiment, which suggests that the pH value affects the cell culture significantly.
6.4 Model simulation
Model simulation was performed in gPROMS, and the simulation results were
compared to the experimental results in order to examine the quality of data
fitting. Intracellular metabolite concentrations for day 4 were shown in Table
6.5. The simulation Glc uptake flux rate 1565.22 mM{d is 3.7% smaller than the
flux rate 1625.22 mM{d used for parameter calculation. Most of the simulation
results were comparable to the ones reported in literature.
Figure 6.3 shows the comparison of model prediction to the growth curves
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Table 6.5: Intracellular metabolite concentrations for CHO cells
Concentration (mM)
Metabolite In literature Simulation Difference
13BPG 0.005 ˚ 0.0044 -11.7%
23BPG 0.051 ˚ 0.0447 -12.4%
2PGA 0.005 [145,146] 0.0045 -10.0%
3PGA 0.040„0.048 [145,146] 0.0362 -9.3%„-24.4%
6PG 0.018 [68] 0.0197 +9.4%
6PGL 0.080 ˚ 0.0942 17.8%
DHAP 0.040-0.046 [145,146] 0.0465 1.1%„16.25%
E4P 0.004 [68] 0.0043 6.5%
F16BP 0.046 [145,146] 0.0473 2.8%
F6P 0.362 [145,146] 0.3532 -2.4%
G6P 1.033 [145,146] 0.6964 -32.6%
GA3P 0.021 [144] 0.0244 16.2%
Glc 2.377 [145,146] 0.4525 -81%
Lac 2.660„6.700 [145,146] 2.9289 -56.3%„10%
PEP 0.008 [145,146] 0.0069 -13.8%
Pyr 0.056 [145,146] 0.0303 -45.9%
R5P 0.009 [68] 0.0095 5.6%
Ru5P 0.012 [68] 0.0128 6.7%
S7P 0.068 [68] 0.0645 -5.1%
X5P 0.018 [68] 0.0188 4.4%
˚ Assumed to in Table 6.2
in both unlabelled and labelled experiments (see Figure 5.1). Experimental and
simulation results for labelled experiment started from Day 3.09, when the labelled
Glc was fed into the culture. However, as shown in Figure 6.3, the simulation
results do not agree completely with experimental results well in cell decline phase.
The cell death rate in the decline phase increases rapidly in vitro. However, during
the that phase, cell metabolism slows down and thus ammonia concentration
increases slowly, which based on Monod kinetics, results in slowly increasing cell
death rate in silico. Given that this study focuses on the exponential cell growth
phase, no modification was done for cell death kinetics. However, it is suggested
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that the Monod kinetics for cell death need to be improved for predicting cell
population behaviour throughout the cell culture duration.
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Figure 6.3: Comparison of model simulation to experimental GS-CHO cells growth
curve in CD-CHO media in (a) unlabelled (5% CO2) and (b) labelled (8% CO2)
experiments
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Figure 6.4: Comparison of model simulation to experimental extracellular Glc
concentration of GS-CHO cells in CD-CHO media in (a) unlabelled (5% CO2)
and (b) labelled (8% CO2) experiments
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Figure 6.5: Comparison of model simulation to experimental extracellular Lac
concentration of GS-CHO cells in CD-CHO media in (a) unlabelled (5% CO2)
and (b) labelled (8% CO2) experiments
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Figure 6.6: Comparison of model simulation to experimental extracellular ammonia
concentration of GS-CHO cells in CD-CHO media in (a) unlabelled (5% CO2)
and (b) labelled (8% CO2) experiments
Figures 6.4-6.6 show the comparison of experimental (see Figure 5.2(b)-(d)
and Figure 5.4(a)(b)) and simulation results of extracellular Glc, extracellular
Lac and extracellular ammonia. Extracellular ammonia concentration was only
analysed for unlabelled experiment.
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As shown in Figure 6.4, the simulation results in cell decline phase do not
agree with the experimental data well. And taken into account that intracellular
Glc concentration reported in Figure 6.4, the simulation results of intracellular
Glc concentratios are much lower than the experimental results.
As shown in Figure 6.5(a), the simulation results do not agree with the
experimental data as well as in Figure 6.5(b) , which implies that in the cellular
metabolism, the production of Lac is regulated. As shown in Equation 3.27, the
regulator might be the NAD`/NADH ratio. More experiment is suggested to
monitor the changes of NAD` and NADH. Furthermore, there is also a possibility
that the transport rate expression is not correct for the Lac transport.
This model is novel in combining not only intracellular and extracellular
information, but also micro level and macro level information. As there are no any
good examples focus on the similar system, to solve the problem of low quality
fitting, it is necessary to have more experiment results as well as good kinetic
information, e.g. transport kinetic for Lac to get a better fit for extracellular Lac.
Comparison of experimental (see Figure 5.6(f)) and simulation results of
intracellular Lac was shown in Figure 6.7. Intracellular ammonia concentration
was only analysed for labelled experiment. In Figure 6.7(b), the intracellular Lac
concentration increase slowly. This is due to the fact that in labelled experiment,
the saturation extracellular Lac concentration rLacsex,max is much smaller than the
one in unlabelled experiment, the transport rate of Lac out of cells is low at the end
of exponential phase and the small V 1LDH,max value, and thus results in intracellular
Lac accumulation, which shows good agreement with the experimental results.
Comparison of the simulation and the experimental (see Figure 5.6(c)) results
of intracellular Glc was shown in Figure 6.8. Both Figures 6.8(a) and (b) show
that the intracellular Glc concentration decrease during the whole cell culture
steadily and shows the same behaviour as extracellular Glc in Figure 6.4, which
indicates that the metabolism rate decrease during the whole cell culture.
However, the simulation result of Glc concentration is much lower than the
reported one (see Figure 5.6(c)). It is because in the reaction catalysed by
hexokinase (Equation 3.12), the used KGlcHK,m “ 0.11 mM is much smaller than the
reported intracellular Glc concentration 2.377 mM . [145,146] There are four different
types of HK with different KGlcHK,m values, and K
Glc
HK,m values for HK IV (GCK) is
95
6.4 Model simulation
0 2 4 6 8 10 121
1.5
2
2.5
3
In
tra
ce
llu
la
r l
ac
ta
te
co
n
ce
n
tra
tio
n 
(m
M)
(a)
 
 
3 4 5 6 7 8 9 100
2
4
6
8
In
tra
ce
llu
la
r l
ac
ta
te
co
n
ce
n
tra
tio
n 
(m
M)
(b)
 
 
Experiment
Fitting
Experiment
Figure 6.7: Comparison of model simulation to experimental intracellular Lac
concentration of GS-CHO cells in CD-CHO media in (a) unlabelled (5% CO2)
and (b) labelled (8% CO2) experiments
0 2 4 6 8 10 120
2
4
6
Day
In
tra
ce
llu
la
r g
lu
co
se
co
n
ce
n
tra
tio
n 
(m
M)
(a)
 
 
3 4 5 6 7 8 9 100
0.5
1.0
1.5
Day
In
tra
ce
llu
la
r g
lu
co
se
co
n
ce
n
tra
tio
n 
(m
M)
(b)
 
 
Simulation
Experiment
Fitting
Figure 6.8: Comparison of model simulation to experimental intracellular Glc
concentration of GS-CHO cells in CD-CHO media in (a) unlabelled (5% CO2)
and (b) labelled (8% CO2) experiments
much larger than the rest, which implies that the intracellular Glc concentration
is the result of the combination of the four types of HK other than only one. Due
to the low concentration of Glc, the concentration of G6P is much lower than
the reported one. Furthermore, the concentration of Pyr is much lower than the
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reported one due to the missing of regulation of the flux rate entering the TCA
cycle.
6.5 Conclusion
The simulation results show good agreement with the experimental data. Although
the simulation results and experimental results for intracellular Glc show some
difference, they are still of the same magnitude. The parameterised model, to
some extent, has provided a tool for the studies of cell population, extracellular
metabolites and intracellular metabolism in CHO cell culture. Furthermore, it
can also be modified for studies of other cell lines.
However, due to the insufficient intracellular metabolome information, most
of the simulation for intracellular metabolites were unable to validate. More
experiments with proper metabolomic analysis techniques should be carried out.
With sufficient experimental data, the model could also be extended to include
other metabolic pathways.
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Chapter 7
Model-Based Studies
As the following step of model construction, utilization of the established model
is also important. Mathematical modelling is not only modelling the system but
also acting as a tool to study the system, which is the final goal of the modelling
study.
7.1 Global sensitivity analysis
7.1.1 GSA results
SA is the study of how much the uncertainty of inputs of the model will contribute
to the uncertainty of the outputs. [79] Sensitivity analysis methods were described
and summarized in Section 2.3. The objective function u “ f pxq is set up and x
is all kinetic parameters considered in the model, e.g., Km, Ki, Vmax, etc, from
literature, calculated and estimated, and the concentrations of nucleotides that
were assumed to be stable. The total number of parameters is 159 while the total
number of objective function is 27. Parameter space was defined as ˘90%. And
the parameters, the inputs of the functions, were grouped into 3 groups:
1. d for cell diameter;
2. the parameters of the intracellular metabolism, namely all Vmax, Km, Ki for
intracellular reactions and the fixed intracellular concentrations, e.g., [ATP]
and [ADP.].
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3. the parameters of cell growth and death, e.g., parameter for Glc and Lac
transport and maximum cell death rates.
Figure 7.1 shows the DGSM results (only DGSM G¯i ą 0.01 for day 3 or
day 6 shown) using viable cell concentration Xv as outputs of interests. Besides
the obvious ones like the parameters relating to Glc uptake, the intracellular
metabolism is sensitive in exponential phase (day 3, Figure 7.1(a)), and at day
6 (Figure 7.1(b)). The importance of intracellular metabolism decreases as the
whole metabolism slows down.
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Figure 7.1: DGSM result for viable cell concentration Xv as target function on
(a) day 3 and (b) day 6
Comparing the global sensitivity indices on day 3 and day 6 for viable cell
concentration, Xv, in Figures 7.1 (a) and (b), a significant difference is that the
importance of cell diameter decreases significantly, while the parameters directly
related to cell growth and Glc uptake increase. The importance of intracellular
metabolism remained at a low level, and only 2 Km and 2 Vmax have DGSM
G¯i ą 0.01.
Figures 7.2 and 7.3 show the DGSM results (only DGSM G¯i ą 0.01 for
day 3 or day 6 were shown) used the extracellular Glc and Lac as the target
functions. Similar to the results for the viable cell concentrations in Figure 7.1,
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intracellular metabolism contributes more for sensitivity indices in the exponential
phase than the peak day when metabolism has slowed down. However, in
contrast, intracellular metabolism was sensitive to extracellular Lac, a by-product
of metabolism.
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Figure 7.2: DGSM result for extracellular Glc concentration as target function on
(a) day 3 and (b) day 6
As Glc is the only nutrient for cell growth considered in the model, the
sensitivity indices for extracellular Glc have a similar pattern as the viable cell
concentration. The dominant sensitivity index is cell diameter on day 3 with
decreasing significance on day 6. The parameters related to cell growth and
Glc uptake showed dominant importance on day 6. Compared to the sensitivity
indices for viable cell concentrations, the biggest difference is the index of nAmmµd ,
the Hill coefficient of ammonia for the specific cell death rate expression. Based on
the results, the maximum cell death rate would affect the extracellular behaviour
significantly.
As a by-product that is located at the end of the metabolic map, the sensitivity
indices for extracellular Lac as a target output did not show as much difference
as for the viable cell concentration and the extracellular Glc. The significant
sensitivity indices correspond to parameters belonging to intracellular metabolism,
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Figure 7.3: DGSM result for extracellular Lac concentration as target function on
(a) day 3 and (b) day 6
and having increasing trends from day 3 to day 6. However, the parameters for
cell growth and Glc uptake were still shown to be strong as they showed the
viable cell concentrations and the extracellular Glc.
For intracellular metabolites, Glc was selected as an example and shown in
Figure 7.4 (only DGSM G¯i ą 0.01 for day 3 or day 6 were shown). The results
indicated that the cell size was the most sensitive parameter in the model, which
was because it would hugely change the inlet and outlet flux of the intracellular
metabolic system. Interestingly, in Figures 7.4(a) and 7.4(b) showed similar
behaviour, and besides cell size, the parameters with high sensitivity indices
belong to the enzymatic kinetics close to intracellular Glc.
Interestingly, the sensitivity indices for parameters with respect to intracellular
Lac concentration on day 3 and day 6 are very similar. Cell diameter is still the
dominant parameter. The results show that intracellular enzyme kinetics affect
Lac concentration severely, while the parameters for cell growth and death have
relatively low sensitivity indices, which suggests that intracellular metabolism has
strong modularity in order to maintain cellular activity at certain level and show
robustness in the changes in the extracellular environment.
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Figure 7.4: DGSM result for intracellular Glc concentration as target function on
(a) day 3 and (b) day 6
7.1.2 Discussion
GSA results can be used as the guide of model-based experiment design as well as
model improvement. Coupled with difficulties of changing the parameter values
experimentally, including time and cost, parameters with high GSA results can
be used as starting point.
In Figures 7.1-7.4, cell diameter d shows very high sensitivity to all the
different target functions. It is because of that the cell size affects the intracellular
concentrations directly. However, it also suggests that the assumption that all
the cells have same diameter (see Section 2.2.4) could be improved by introducing
subpopulation of different cell sizes and cell cycle stages. A flow cytometer can be
employed to analyse the cell size distribution experimentally and the experimental
result can be used for a population balance modelling for macro level model.
102
7.2 Feeding Lac for cell culture
7.2 Feeding Lac for cell culture
7.2.1 Simulation results
Lac is generally considered as a by-product of glycolysis. Glc degrades into Lac
under anaerobic environment, for complete degradation in the TCA cycle requires
oxygen. Lac is also considered as a inhibitor in Monod kinetics. Thus, cell culture
media are generally Lac-free, e.g., the CD-CHO media used.
Although the constructed model does not include O2 and CO2, it is still possible
to provide a different angle of view to Lac. In some cell culture models, the yield
of Lac over Glc was considered as a constant. Here, based on the simulation
result, yield of Lac over Glc
YLac{Glc “ qLac
qGlc
(7.1)
is plotted in Figure 7.5. It is clear that YLac{Glc is not a constant and it is much
higher at the early stage of the culture.
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Figure 7.5: Simulation result of yield of Lac over Glc in batch culture for (a)
unlabelled and (b) labelled experiment
It is clear that at the early stage of cell culture process, larger amount of the Glc
uptaken into cells degrades into Lac. And when the extracellular Lac concentration
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increases, qLac decreases, which implies that a reasonable concentration of Lac
in the media would increase the efficiency of Glc utilisation. Hence, initial
extracellular Lac concentration in the model was adjusted to 5 mM and 10 mM ,
and the simulation results were compared and shown in Figures 7.6 and 7.7.
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Figure 7.6: Simulation result of yield of Lac over Glc under different initial
extracellular Lac concentrations
With certain initial extracellular Lac, the cell growth curves have higher and
earlier peaks. Kinetically, the cells produce lactic acid other than its conjugate
base Lac. Thus the produced Lac would change the pH value of the media and
inhibit the cell growth.
7.2.2 Discussion
Lac is generally considered as an inhibitor of the cell growth, based on which
feeding Lac to the cell culture would inhibit the cell growth. However, the
simulation of the model showed different results. The simulation results suggested
that a suitable concentration of extracellular Lac could increase the cell culture
efficiency. A recent study [151] has experimentally proven that other than using
Lac-free media, a suitable feeding strategy for Lac into the media in CHO cell
culture does have a positive impact to cell culture. Attention must be paid that
when feeding Lac into culture, pH value must be monitored and adjusted.
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Figure 7.7: Simulation result of viable cell concentrations under different initial
extracellular Lac concentrations
7.3 Allosteric regulation of PFK1 by F26BP
7.3.1 Simulation results
F26BP exists in numerous cell lines including mammals, some fungi and plants,
but not in prokaryotes. [152] According to KEGG, this metabolite and the related
enzyme phosphofructokinase-2 (PFK2, EC 2.7.1.105) have not been reported to
be present in S. cerevisiae cells. F26BP allosterically regulates glycolysis. When
present in high concentrations, it stimulates the activity of PFK1 by changing
the Hill coefficient, nF6PPFK1, shown in Equation 3.15.
In contrast, at low concentrations F26BP inhibits glycolysis and stimulates glu-
coneogenesis, the inverse pathway of glycolysis. [114] Based on data in literature, [149]
shown in Figure 7.8, we deduced two correlations between KF6PPFK1,m, n
F6P
PFK1 and
the concentration of F26BP, which was valid between 0 nM and 6.4 nM . Based
on the deduced correlations, reaction rates of reaction PFK1 vPFK1 under different
F6P concentration with different F26BP concentrations were shown in Figure 7.9,
and it was clear that F26BP accelerated vPFK1 (see the direction of the arrow in
Figure 7.9).
The model for unlabelled experiment described in Section 6.3 was used to
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Figure 7.9: Reaction rate vPFK1 under different F26BP concentrations
simulate under different F26BP concentrations. However, as shown in Figure
7.10, the growth curves of the cells actually slowed down with postponed peak
times and lower peak values when the F26BP concentration were higher (as
the arrow showed). Based on the viable cell concentration, the IVC values
at day 12 were calculated as 2.4329 ˆ 1010 cells ¨ d{L, 2.4346 ˆ 1010 cells ¨ d{L,
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2.4371ˆ1010 cells ¨d{L and 2.4383ˆ1010 cells ¨d{L under 0 nM , 2 nM , 4 nM and
6 nM F26BP, respectively. The IVC results showed less than 0.22% differences.
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Figure 7.10: Viable cell concentration Xv under different F26BP concentrations
To study why the cell growth slowed down when F26BP accelerated the
reaction PFK1, concentrations of extracellular Glc, Lac and intracellular F6P,
F16B were plotted in Figure 7.11. F6P concentration decreased significantly (see
Figure 7.11(c)) because of the decrease of KF6PPFK1,m (see Figure 7.8). However, the
concentration of F16BP increased (see Figure 7.11(d)), which denoted that the
metabolic flux rates increased (see Figure 7.12(a)) and more Lac were produced,
as shown in Figure 7.11(b). The consumption of extracellular Glc was based on
the diffusion and it only changed slightly (see Figure 7.11(a)).
Figure 7.12 showed two typical reaction rates under different F26BP concentra-
tions. Both of the reaction rates increased when F26BP concentration increased.
However, as more Lac was generated, less energy was produced, which resulted in
the slow down of the cell growth, as shown in Figure 7.10. As shown in Equation
3.5, the increase of Lac production rate would result in decrease of the specific
growth rate.
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Figure 7.11: Metabolite concentrations (a) extracellular Glc, (b) extracellular
Lac, (c) intracellular F6P and (d) intracellular F16BP under different F26BP
concentrations.
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Figure 7.12: Reaction rate (a) vPFK1 and (b) vLDH under different F26BP concen-
trations
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7.3.2 Discussion
This result suggested that accelerating reaction by means of increasing the accel-
erators or decreasing the inhibitors might not necessarily increase the cell growth.
Acceleration of a single reaction could possibly increase the uptake rate. But
could also increase the production rate of toxic by-products, i.e. it would not
necessarily increase metabolic efficiency.
7.4 Conclusion
Biological systems are complicated and all the metabolites affect each other. The
case studies presented here show that the empirical methods like removing the by-
products from the system or accelerating a single forward reaction could possibly
be in the wrong direction for improving the cell culture process. Model-based
simulation and system analysis is a valuable tool of studying biological systems
and a guide of real-life experiments.
As for cell culture optimisation, the GSA results show that the Glc and Lac
transport, and the cell death affect the cell culture significantly and have much
greater importance than intracellular metabolism. Hence, media formulation and
the environment should be the first step. As seen in the parameter estimation
results, the CO2 concentration strongly affects the parameter estimation results.
It is suggested that the extracellular media and the environment should be closely
monitored. Secondly, the GSA results show that some parameter for intracellular
metabolism have big DGSM values, e.g., VHK,max and VPGK,max, which should be
chosen for optimisation mathematically and experimentally.
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Chapter 8
Model for Saccharomyces
cerevisiae cells
A similar but simpler study was performed to another industry relevant cell-line
S. cerevisiae, in order to examine the capability and reliability of kinetic model.
8.1 Model building for S. cerevisiae cells
Based on KEGG, the map of cytosolic glucose metabolism in S. cerevisiae cells
was built as shown in Figure 8.1. This includes glycolysis and the PPP. Because
of the limitation of metabolite concentrations and the kinetic parameters, only
forward reactions have been taken into account in the model formulation.
According to Table 8.1, in S. cerevisiae cells, the concentrations of 13BPG,
6PGL, Ru5P, R5P and X5P have not been reported experimentally, while E4P and
S7P were reported as not detectable experimentally. [153] Moreover, no experiment
for S. cerevisiae cells was carried out in this project for intracellular metabolite
concentration and enzyme enzyme kinetics. To avoid inaccuracies and overfitting
of kinetic parameters, the metabolic model was reduced by grouping certain
adjacent reactions. Hence, the reaction catalysed by PGK was grouped with the
previous reaction catalysed by GADPH, and the entire PPP pathway was grouped
since there is little information for metabolite concentrations in the PPP. The
revised metabolic map is shown in Figure 8.2.
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Figure 8.1: Cytosolic glucose metabolic map of S. cerevisiae cells
Metabolic flux analysis studies have showed that besides inlet glucose and
outlet pyruvate, the metabolic fluxes exiting glycolysis and the PPP are still
considerable [107,154--156] and therefore need to be taken into account in the model.
Based on the reconstructed metabolic map and fluxes reported in literature, [107,156]
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Table 8.1: Intracellular metabolite concentrations for S. cerevisiae cells
Metabolite Conc. (mM) Ref. Metabolite Conc. (mM) Ref.
2PGA 0.005 145,146 Glc 2.377 145,146
3PGA 0.040-0.048 145,146 Gly3P 0.168 145,146
6PG 0.018 68 Lac 2.660-6.700 145,146
ADP 1.059 145,146 NAD` 0.31 145,146
ATP 3.075 145,146 Pi 5.5 145,146
DHAP 0.040-0.046 145,146 PEP 0.008 145,146
E4P 0.004 68 Pyr 0.056 145,146
F16BP 0.046 145,146 R5P 0.009 68
F6P 0.362 145,146 Ru5P 0.012 68
G1P 0.065 145,146 S7P 0.068 68
G6P 1.033 145,146 X5P 0.018 68
GA3P 0.021 144
the set of Fin,i and Fout,i considered in the model for S. cerevisiae are:
1. FGlc,in: feed of glucose from media via trans-membrane transport,
2. FG6P,out: reactions towards nucleotide sugar donor metabolism and the PPP,
3. FF6P,in: reactions from the PPP,
4. FF6P: reactions towards synthesis of fructose 2,6-bisphosphate,
5. FGA3P,in: reactions from the PPP,
6. FGA3P,out: reactions towards the PPP,
7. FDHAP,out: reactions towards synthesis of glycerol,
8. F13BPG,out: reactions towards synthesis of amino acids,
9. FPyr,out: reactions towards synthesis of lactate, the TCA cycle, etc.
Enzyme kinetics in literatures were searched starting with BRENDA and
summarized in Table 8.2.
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Table 8.2: Kinetic reaction rate expression for S. cerevisiae cells
Kinetic expression Parameters
vHK “ VHK,max´
1` KGlcHK,mrGlcs
¯ ”
1` KATPHK,mrATPs
´
1` rADPs
KADPHK,i
¯ı KGlcHK,m “ 0.13 mM , [157]
KATPHK,m “ 0.10 mM , [157]
KADPHK,i “ 0.122 mM . [157]
vGPI “ VGPI,max
1` KG6Pm,GPIrG6Ps
´
1` rF6Ps
KF6PGPI,i
¯ KG6Pm,GPI “ 0.700 mM , [158]
KF6PGPI,i “ 0.040 mM . [158]
vPFK1 “ VPFK1,max´
1` KF6PPFK1,mrF6Ps
¯´
1` KATPPFK1,mrATPs
¯ KF6PPFK1,m “ 0.58 mM , [159]
KATPPFK1,m “ 0.033 mM . [159]
vALD “ VALD,max
1` KF16BPALD,mrF16BPs
KF16BPALD,m “ 0.45 mM . [160]
vTPI “ VTPI,max
1` KDHAPTPI,mrDHAPs
´ V
1
TPI,max
1` KGA3PTPI,mrGA3Ps
KGA3PTPI,m “ 1.1 mM , [161]
KDHAPTPI,m “ 2.1 mM , [161]
kcat “ 4.7 s´1, [161]
k1cat “ 0.5 s´1. [161]
vGADPH “ VGADPH,max
1` KGA3PGADPH,mrGA3Ps
KGA3PGADPH,m “ 0.6 mM . [162]
vPGM “ VPGM,max
1` K3PGPGM,mr3PGs
K3PGPGM,m “ 0.65 mM . [163]
vENO “ VENO,max
1` K2PGENO,mr2PGs
K2PGENO,m “ 0.3 mM . [164]
vPK “ VPK,max´
1` KPEPPK,mrPEPs
¯´
1` KADPPK,mrADPs
¯ KPEPPK,m “ 0.099 mM , [165]
KADPPK,m “ 0.16 mM . [165]
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8.2 Parameter calculation and model simulation
for S. cerevisiae cells
Various different values for the metabolic flux entering the PPP have been
reported for S. cerevisiae cells, e.g., 2.5% [154], 1.3%-2.8% [155] and 16.2%-44.2% [156].
However, this range is too big for modelling. Therefore, we have chosen to examine
the following three scenarios:
Scenario A: Using the metabolic flux distribution towards the PPP 16.2% [156]
for parameter estimation because this is one of the few studies conducted
in a defined fermentation medium. Samples were removed from the batch
cultivation at the late exponential phase. The reported metabolic fluxes
were converted herein to units of mM{s using a cell density equal to
1.1029 g{mL [166] and water content of 67% [167].
Scenario B: Using half of the metabolic flux towards the PPP in scenario A,
i.e., 8.1%.
Scenario C: Using 2.4% [155] as the metabolic flux distribution towards the PPP.
The calculated metabolic flux distributions for 3 scenarios are presented
in Figure 8.2. Based on the available information, including the metabolite
concentrations in Table 8.1, the enzyme kinetics in Table 8.2 and calculated
metabolic fluxes results in Figure 8.2, the apparent Vmax values in the model
were estimated in the ‘parameter estimation’ entity in gPROMS (PSE Ltd., U.K.)
based on the assumption that reaction rates are equal to the counterpart net
metabolic flux rates.
The estimated apparent Vmax values for all 3 cases are presented in Table 8.3.
Interestingly, the estimated values for all scenarios are comparable. In most cases
the deviation is within 5%, i.e., within the margin of experimental error. The
most significant deviation occurs in the case of the Vmax for GPI, the enzyme
close to the entry site of the PPP, for which the values under scenarios B and C
differ from that for scenario A by 10.00% and 19.72%, respectively.
However, this result is unsurprising since by reducing the flux to the PPP,
an increased glucose flux will be channeled to the main glycolytic pathway. As
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Figure 8.2: Cytosolic glucose metabolic map of S. cerevisiae cells
shown in Figure 8.2, in the main glycolytic pathway, only the fluxes from G6P
to F6P differ at a high level in 3 different scenarios. Similarly, this increases the
Vmax for PFK1 and ALD, which catalyze the following two reactions in glycolysis.
However, because of the high outlet flux rate towards glycerol in scenario C, the
effect of reduced the PPP flux changes the Vmax values for the remaining enzymes
in opposite ways, with values increasing under scenario B and decreasing under
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scenario C. Similarly, as shown in Figure 8.2, the difference of Fin,i and Fout,i
significantly affects our estimation for apparent Vmax values in the latter glycolytic
pathway.
Table 8.3: Estimated apparent Vmax values in S. cerevisiae cells
Scenario A Scenario B Scenario C
Enzymes Vmax Vmax Diff. (%) Vmax Diff. (%)
HK 0.0175 0.0175 0.00 0.0175 0.00
GPI 0.0614 0.0676 +10.00 0.0735 +19.72
PFK1 0.0215 0.0223 +3.41 0.0231 +7.43
ALD 0.0140 0.0144 +3.41 0.0150 +7.43
TPI 0.0968 0.1003 +3.62 0.0917 -5.27
GADPH 0.0546 0.0557 +2.14 0.0543 -0.53
PGM 0.1637 0.1672 +2.14 0.1593 -2.72
ENO 0.0374 0.0382 +2.14 0.0364 -2.72
PK 0.1398 0.1428 +2.16 0.1339 -4.23
8.3 Model-based studies for S. cerevisiae cells
As an important metabolite and intermediate in the synthesis of fine chemicals,
DHAP was chosen as product for optimization study. To increase the DHAP
production, an obvious attempt is to limit the reaction catalyzed by TPI towards
GA3P in the way of delete the TPI enzyme, an attempted previously described
in a a cell-free study [168]. This was achieved by setting the value for Vmax,TPI
equal to zero in the model. The glucose uptake rate, qGlc was varied between
0.1 µM and 20 µM (approximately twice as reported [156] and in Figure 8.2).
Metabolite concentrations in Table 8.1 were used as initial values and the system
was simulated until it reached steady-state. As an optimization study of DHAP
production, two outputs, namely the steady-state DHAP accumulation rate
d rDHAPs{dt and yield of DHAP over Glucose YDHAP,Glc, were examined are
shown in Figure 8.3.
At about qGlc “ 0.0155 mM{s, DHAP accumulation rate stops increasing
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Figure 8.3: DHAP accumulation rate and yield over glucose with no TPI enzyme
under different glucose uptake rates
because of the limitation of the low Vmax values in the early part of glycolysis
while YDHAP,Glc reaches the peak value of 0.965, which is close to the theoretical
maximum value of 1. The maximum for d rDHAPs{dt calculated in this way
is 28% higher than the experimental flux in Figure 8.2, which implies that the
efficiency of S. cerevisiae metabolism can be improved. And there is no significant
difference between the fluxes and metabolite concentrations in the early part of
glycolysis in the presence and absence of TPI enzyme, which is caused by the
omission of rates for the backward reactions and the regulation (inhibition) in
glycolysis and the PPP.
8.4 Conclusion
The model for GS-CHO cells has been sucessfully adapted for S. cerevisiae cells,
which indicates that with necessary adaptions, the model for GS-CHO cells is a
framework which can be adapted for other organism. Based on the constructed
model for S. cerevisiae, a novel model based study was performed to analyse the
cell operating condition, which indicated that the cell metabolism is operating
close to the theoretical maximum condition. It also suggested that it would be
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hard to increase the cell metabolism without modifying the enzyme concentrations
inside the cells.
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Chapter 9
Conclusions and Outlook
9.1 Summary of results
This thesis presented a genome-based kinetic model for GS-CHO cells. The
intracellular metabolism and extracellular population infomation, which were
generally treated as two seperate models, were directly linked using a novel
attempt, namely transmembrane transport of nutrients and products. This
enables the metabolic behavior analysis between intracellular metabolites and the
cell growth information, which is not possible for models that treat the intracellular
and extracellular environments separately.
Based on the reported enzyme existence and kinetics in CHO cells, a model
for cytosolic glucose metabolism was constructed. Michaelis-Menten kinetics were
used for calculation of all 24 reaction rates, in which enzyme inhibition/acceleration
by other intracellular metabolites were also considered. The model introduced
population level information by means of employing transmembrane transport for
glucose and lactate which directly linked the extracellular glucose consumption
and lactate accumulation to the cytosolic glucose metabolism. As ammonia was
not directly linked to the cytosolic glucose metabolism, the yield of ammonia on
viable cell metabolism was introduced to simulate ammonia production. For cell
growth, a new strategy of calculation of the specific cell growth rate using the
energy production was developed, as shown in Equation 3.5. This new relation for
specific cell growth showed a good capability for predicting the cell growth rate.
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In order to parameterise the model, metabolomic analysis was performed. Sam-
ples from fed-batch CHO cell cultures were quenched and intracellular metabolites
were extracted. GC/MS analysis was then performed to analyse the dynamic
intracellular metabolome. Metabolite standards were used to identify and anal-
yse the GC/MS results of the cell extracts. However, the results showed that
most of the intracellular metabolites in cytosolic glucose metabolism could not
be detected/quantified. As the GC/MS for metabolite standards showed that
detection and quantification was possible, extra analysis including increasing the
sampling amount, removing washing step for quenching and changing the injection
strategy of GC/MS, was performed. The results showed that due to the fast
reaction rates, the intracellular metabolites in cytosolic glucose metabolism could
not be quantified. Based on reported enzymatic kinetics and own experiments,
parameter calculation and estimation were performed in MATLAB and gPROMS
to parameterise the model.
Based on the constructed model and calculated/estimated parameters, global
sensitivity analysis and two model-based studies: feeding lactate into the media
as macro level study and the regulation of PFK1 by F26BP as micro level study.
GSA results provided a direction of cell culture process optimisation for both
culture feeding strategy and genome engineering. The two case studies predicted
that feeding lactate into the cell culture could positively affect the cell culture
process while accelerating a forward reaction negatively affected the cell culture
process, which are different from our previous intuitive thinking.
Compared to the trial-and-error studies for biological systems, the model has
provided a new angle of view to look into the cells. As enzymatic kinetics including
inhibition and acceleration was employed in the model, the metabolites interacted
with each others. As an extension of the model, the model was simplified and
adapted for another industrial relevant cell line S. cerevisiae cells.
9.2 Conclusions
Kinetic modelling is a demanding yet powerful method to study cellular meta-
bolism and related bioprocessing applications. Herein, it was examined how it
can be applied to analyses extracellular culture data for two commonly used cell
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lines. It is additionally demonstrated that its potential usefulness for analysing
genetic manipulation effects and evaluating process operation conditions. When
coupled with meaningful experiments, kinetic modelling can therefore facilitate
our understanding of regulation effects and help optimise cell culture conditions.
However, considerable computational and experimental work is still required to
enrich related enzyme databases.
Kinetic modelling considered the metabolism and cell growth as a single system
and each element in the system affects each other. The regulation case study
showed that acceleration of a single forward reaction in the network would not
necessarily increase the cell growth, and in this case, it actually decreased the
cell growth rate. The model provides a good guide for cell culture optimisation
mathematically and experimentally. In contrast, experiment could also help to
improve the model.
9.3 Suggestions for future work
9.3.1 Future experiment directions
More informative cell culture experiments for extracellular and intracellular anal-
ysis should be preformed for parameter estimation and model validation.
In this study, metabolomic study was performed trying to analyse the dynamic
intracellular metabolite concentrations. However, for intracellular metabolites,
only glucose and lactate were quantified. A better quenching/extraction methods
should be developed and employed. The collection of high-quality dynamic data
through the whole cell culture on both extracellular and intracellular metabolite
concentrations, in conjunction with a transcriptomic analysis on the metabolic
enzymes, can enable the accurate determination of the kinetics of each enzyme
involved using model-based network analysis. However, it is still difficult for
collecting high-quality data due to the limitation of the techniques. Larger
sampling amount and larger culture volume are needed. Hence, switching to a
bioreactor would be a good choice.
As the experiment done in this study is under 5% and 8% CO2 concentrations,
parameter estimation could not be done at in the same estimation process as the
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parameter values could be different. As discussed in Section 6.3, the approaches
like determining if extracellular lactate lactate concentration should be included
in the calculation of specific cell death rate, extra experiment should be done. A
strategy is that feeding different initial lactate into the media under the same
CO2 concentration condition, in which pH value should be monitored. Hence,
parameter estimation could be done for both kinetic determination and support
the modelling prediction that feeding initial lactate into the media could help
improved the cell culture process.
As suggested by the GSA studies in Section 7.1, cell diameter affects the
output of the model significantly. In order to improve the model, flow cytometry
should be introduced to analyse the cell size and cell cycle stage distributions.
9.3.2 Future modelling directions
This model is only for cytosolic glucose metabolism, which is essential but only a
part of the whole metabolic map. Hence, a more complete map for cell metabolism
should be considered. The first pathway should be introduced into the model
is the TCA cycle. This is a special glucose metabolism pathway as it is in
mitochondria. It is the following pathway of cytosolic glucose metabolism and
where glucose generates most energy. As described in Section 3.1, a separate model
for TCA should be built and link to the model in cytosol via trans-membrane
transport. Furthermore, as some metabolites and enzymes of TCA cycle also exist
in cytosol, additional attention needs to be paid. Other metabolic pathways like
amino acid metabolism can be considered as an extension of the current model.
However, unlike glycolysis, amino acid metabolism consists of a great number
of reactions that have not been studied sufficiently. Reaction grouping could be
introduced to overcome this problem. The GC/MC results for intracellular and
extracellular amino acids showed that it is possible to obtain dynamic profiles of
these metabolites that can help populate the metabolic model.
As shown in Figure 6.3 in Section 6.4, the simulation result of cell growth curve
does not fit the experimental data in cell death phase. In cell death phase, specific
cell death rate increased slowly as well as the extracellular ammonia concentration.
However, as shown in Figure 6.3, specific cell death rate still increased in cell
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death phase, which implied that rather than extracellular ammonia, there were
some other metabolites or environmental parameters contributed to the cell death
e.g., dead cells.
As transmembrane transport is crucial in the model, a better understanding
of transmembrane of both Glc and Lac is needed for modelling. As transmem-
brane Glc transport is single directional and transmembrane Lac transport is
bi-directional, extra attention is needed for transport of Lac. And the simulation
results is not good for extracellular Lac. Hence, transport rate expression of Lac
transport needs improvement.
As suggested in Section 9.3.1, cell size and cell cycle stage distributions would
be analyse experimentally. Hence, the population infomation of the model needs
to be improved to a PBM, taken into account the subpopulations of different cell
sizes and cell cycle stages.
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Appendix B: Mass Spectrometry
Library
This mass spectrometry was created based on the experimental result in this study
and confirmed with Wiely 275 library and Mass Bank online mass spectrometry
database (http://www.massbank.jp/). Retention time for each metabolite were
summarized in Table B.1.
Table B.1: Retention time and detectability of metabolites and internal standards
Split Injection Splitless Injection
Metabolite RT˚ (min) Std˚ In˚ Ex˚ RT (min) In Ex§
23BPG: -˚ N˚ - - - - -
2Fluoro; 9.14 Y˚ Y Y 9.92 Y Y
2PGA: 14.29 Y N N - N N
3PGA: 14.55 Y N N - N N
Ala 9.99 - Y N 10.97 Y N
Asp 11.21 - Y Y 12.22 Y N
DHAP: 13.86, 13.98 Y N N - N N
E4P: 15.67 Y N N - N N
F16BP: - N N N - N N
F1P: 19.24, 19.27 Y N N - N N
F6P: 19.35 Y N N - N N
Fru: 15.28, 15.38 Y Y N 16.37, 16.47 Y N
continued on next page
125
APPENDIX B: Mass Spectrometry Library
Table B.1. continued from previous page
Split Injection Splitless Injection
Metabolite RT (min) Std In Ex RT (min) In Ex
Fum 8.93 - Y N 9.71 Y N
G16BP: - N N N - N N
G1P: 18.31 Y N N - N N
G6P: 19.44, 19.58 Y N N - N N
GA: 8.84 Y N N - N N
GA3P: 13.59 Y N N - N N
Glc: 15.53, 15.70 Y Y Y 16.60, 16.77 Y Y
Glc13C: 15.53, 15.70 Y Y Y 16.60, 16.77 Y Y
Glu 11.10 - Y N 12.14 Y N
Gly 8.42 Y Y Y 9.45 Y Y
Glyc: 8.07 Y N N - N N
Glyc3P: 14.07 Y Y N 15.07 Y N
Lac: 5.01 Y Y Y 6.48 Y Y
Leu/Ile 7.97 - Y Y 8.83 Y N
MAd27; 14.49 Y Y Y 15.46 Y Y
Mal 10.84 - Y N 12.03 Y N
Met 11.11 - N Y - N N
PEP: 12.21 Y N N - N N
Phe 11.38 - Y Y 12.39 Y Y
Pro 11.15 - Y Y 12.20 Y N
Pyr: 4.85 Y N N - N N
R5P: 17.58 Y N N - N N
Ru5P: 17.53, 17.69 Y N N - N N
Ser 7.73 - Y Y 8.64 Y N
Thr 9.56 - Y Y 10.51 Y Y
Val 7.17 - Y Y - N N
˚ Abbreviations: RT: retention time; Std: standard; In: intracellular;
ex: extracellular; Y: detectable; N: not detectable; -: not applicable
: Metabolite standards used in split experiment
continued on next page
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Table B.1. continued from previous page
Split Injection Splitless Injection
Metabolite RT (min) Std In Ex RT (min) In Ex
; Internal standards
§ Only for CD-CHO media fed with glucose
Table B.2: Mass spectrometry library index
Metabolite Index Metabolite Index Metabolite Index
2Fluoro B.1 G6P B.13 Met B.25
2PGA B.2 GA B.14 PEP B.26
3PGA B.3 GA3P B.15 Phe B.27
Ala B.4 Glc B.16 Pro B.28
Asp B.5 Glc13C B.17 Pyr B.29
DHAP B.6 Gly B.18 R5P B.30
E4P B.7 Glyc B.19 Ru5P B.31
F1P B.8 Glyc3P B.20 Ser B.32
F6P B.9 Lac B.21 Thr B.33
Fru B.10 Leu B.22 Val B.34
Fum B.11 MAd27 B.23
G1P B.12 Mal B.24
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File       :H:\GCMS RESULTS\NING 120330\blank.D
Operator   :  
Acquired   : 30 Mar 2012  20:01     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: blank                                           
Misc Info  : control                                         
Vial Number: 1
8.95 9.00 9.05 9.10 9.15 9.20 9.25 9.30 9.35 9.40
100000
200000
300000
400000
500000
600000
700000
800000
900000
1000000
1100000
Time-->
Abundance TIC: blank.D
  9.14
50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220
0
50000
100000
150000
200000
250000
m/z-->
Abundance
172
75 85
14613312051 63 15799 107 215
Figure B.1: GC/MS data for 2-fluorobiphenyl
File       :H:\GCMS RESULTS\NING 120330\ PGA.D
Operator   :  
Acquired   : 31 Mar 2012   5:08     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: std 2PGA                                        
Misc Info  : metabolite standards analysis                   
Vial Number: 13
14.0614.0814.1014.1214.1414.1614.1814.2014.2214.2414.2614.2814.3014.3214.3414.3614.3814.4014.42
200000
400000
600000
800000
1000000
1200000
140
1600000
Time-->
Abundance TIC: 2PGA.D
 14.29
40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460
0
20000
40000
60000
80000
100000
120000
m/z-->
Abundance
73
299
369
459
387
147
217
316 341
101
19355 431269243129 165
Figure B.2: GC/MS data for 2-phosphoglycerate
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File       :H:\GCMS RESULTS\NING 120330\3PGA.D
Operator   :  
Acquired   : 31 Mar 2012   6:39     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: std 3PGA                                        
Misc Info  : metabolite standards analysis                   
Vial Number: 15
14.50 14.52 14.54 14.56 14.58 14.60 14.62 14.64 14.66 14.68 14.70 14.72 14.74 14.76
200000
400000
600000
800000
1000000
1200000
1400000
1600000
1800000
2000000
Time-->
Abundance TIC: 3PGA.D
 14.55
40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460
0
20000
40000
60000
80000
100000
120000
m/z-->
Abundance
73
357
299
147
227
387
459
101
316
207
43111955 189 253165 271
Figure B.3: GC/MS data for 3-phosphoglycerate
File       :H:\GCMS results\ning 120402\413.D
Operator   :  
Acquired   :  2 Apr 2012  23:34     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: cell 4.1.3                                      
Misc Info  : cell samples                                    
Vial Number: 12
9.80 9.85 9.90 9.95 10.00 10.05 10.10 10.15 10.20 10.25 10.30 10.35 10.40
50000
100000
150000
200000
250000
300000
350000
400000
Time-->
Abundance TIC: 413.D
50 60 70 80 90 100110120130140150160170180190200210220230240250260270280290300310320
0
5000
10000
15000
20000
25000
30000
m/z-->
Abundance
75
174
248
147
290
86
59 133
100 160
117 232 304188 204 314216
Figure B.4: GC/MS data for alanine
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File       :H:\GCMS results\ning 120404\e203.D
Operator   :  
Acquired   :  4 Apr 2012  21:51     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: ex 2.0.3                                        
Misc Info  : extracellular sample                            
Vial Number: 11
10.95 11.00 11.05 11.10 11.15 11.20 11.25 11.30 11.35 11.40 11.45
100000
200000
300000
400000
500000
600000
700000
800000
Time-->
Abundance TIC: e203.D
 11.26
60 80 100 120 140 160 180 200 220 240 260 280 300 320 340
0
10000
20000
30000
40000
50000
60000
m/z-->
Abundance
232
73
100 147 218
202
117 18813359 306292 33417487 160 349245 259
Figure B.5: GC/MS data for asparitate
File       :H:\GCMS RESULTS\NING 20330\DHAP.D
Operator   :  
Acquired   : 31 Mar 2012   3:37     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: std DHAP                                        
Misc Info  : metabolite standards analysis                   
Vial Number: 11
13.65 13.70 13.75 13.80 13.85 13.90 13.95 14.00 14.05 14.10 14.15
100000
200000
300000
400000
50
60
Time-->
Abundance TIC: DHAP.D
 13.86
 13.98
60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400
0
5000
10000
15000
20000
25000
30000
35000
40000
m/z-->
Abundance
73
315
299
400
89
173
211
142
241 37019558 282158 354226115 266 385
Figure B.6: GC/MS data for dihydroxyacetone phosphate
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File       :H:\GCMS RESULTS\NING 120330\E4P.D
Operator   :  
Acquired   : 31 Mar 2012  00:35     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: std E4P                                         
Misc Info  : metabolite standards analysis                   
Vial Number: 7
15.40 15.45 15.50 15.55 15.60 15.65 15.70 15.75 15.80 15.85 15.90 15.95 16.00
200000
400000
600000
800000
1000000
1200000
Time-->
Abundance TIC: E4P.D
 15.67
40 60 80 100 120140 160180 200 220240 260280 300 320340 360380 400 420440 460480 500
0
50000
100000
150000
200000
250000
m/z-->
Abundance
357
73
299
147 276211101
186 387331 50224412854 470429167
Figure B.7: GC/MS data for erythrose 4-phosphate
File       :H:\GCMS RESULTS\NING 120330\F1P.D
Operator   :  
Acquired   : 31 Mar 2012   7:25     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: std F1P                                         
Misc Info  : metabolite standards analysis                   
Vial Number: 16
19.00 19.05 19.10 19.15 19.20 19.25 19.30 19.35 19.40 19.45 19.50 19.55
100000
200000
300000
400000
500000
600000
700000
Time-->
Abundance TIC: F1P.D
 19.27
40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460 480
0
5000
10000
15000
20000
25000
30000
35000
40000
m/z-->
Abundance
73
387
299
147
103 173
217
244
129
414354191 317277 48455
Figure B.8: GC/MS data for fructose 1-phosphate
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File       :H:\GCMS RESULTS\NING 120330\F6P.D
Operator   :  
Acquired   : 31 Mar 2012   2:06     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: std F6P                                         
Misc Info  : metabolite standards analysis                   
Vial Number: 9
19.10 19.15 19.20 19.25 19.30 19.35 19.40 19.45 19.50 19.55 19.60 19.65
200000
400000
600000
800000
1000000
1200000
1400000
1600000
1800000
2000000
2200000
2400000
Time-->
Abundance TIC: F6P.D
 19.35
40 60 80100120140160180200220240260280300320340360380400420440460480500520540560580
0
50000
100000
150000
200000
250000
300000
m/z-->
Abundance
315
73
217
147
357
459
387
103
191 262285 434 487 517169 554409 588
Figure B.9: GC/MS data for fructose 6-phosphate
File       :H:\GCMS RESULTS\NING 120330\Fru.D
Operator   :  
Acquired   : 31 Mar 2012   8:56     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: std Fru                                         
Misc Info  : metabolite standards analysis                   
Vial Number: 18
15.00 15.05 15.10 15.15 15.20 15.25 15.30 15.35 15.40 15.45 15.50 15.55 15.60 15.65 15.70
200000
400000
600000
800000
1000000
1200000
1400000
1600000
1800000
2000000
2200000
2400000
Time-->
Abundance TIC: Fru.D
 15.28
 15.38
40 60 80 100120140160180200220240260280300320340360380400420440460480500520540560
0
50000
100000
150000
200000
250000
300000
350000
m/z-->
Abundance
73
103
217
307
147
277
189 364
335244 554393 464 49243412551
Figure B.10: GC/MS data for fructose
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File       :H:\GCMS results\ning 120402\413.D
Operator   :  
Acquired   :  2 Apr 2012  23:34     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: cell 4.1.3                                      
Misc Info  : cell samples                                    
Vial Number: 12
8.80 8.85 8.90 8.95 9.00 9.05 9.10 9.15 9.20 9.25 9.30 9.35 9.40 9.45 9.50 9.55 9.60 9.65
100000
200000
300000
400000
500000
600000
700000
800000
900000
1000000
1100000
1200000
1300000
Time-->
Abundance TIC: 413.D
50 60 70 80 90100110120130140150160170180190200210220230240250260270280290300310320330340350360
0
5000
10000
15000
20000
25000
30000
35000
m/z-->
Abundance
24575
147
86 133
59 299115103 159 171 359217 268233195 314283
Figure B.11: GC/MS data for fumaric acid
File       :H:\GCMS RESULTS\NING 20330\G1P.D
Operator   :  
Acquired   : 31 Mar 2012   5:53     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: std G1P                                         
Misc Info  : metabolite standards analysis                   
Vial Number: 14
18.10 18.15 18.20 18.25 18.30 18.35 18.40 18.45 18.50 18.55
10000
20000
30000
40000
50000
60000
70000
800 0
90000
100000
Time-->
Abundance TIC: G1P.D
50 60 70 80 90100110120130140150160170180190200210220230240250260270280290300310320330340
0
1000
2000
3000
4000
5000
6000
7000
m/z-->
Abundance
73
217
147
295
191
129
246
59 203103 117 177163 28189 260 334
Figure B.12: GC/MS data for glucose 1-phosphate
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File       :H:\GCMS RESULTS\NING 120330\G6P.D
Operator   :  
Acquired   : 31 Mar 2012   9:41     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: std G6P                                         
Misc Info  : metabolite standards analysis                   
Vial Number: 19
19.10 19.15 19.20 19.25 19.30 19.35 19.40 19.45 19.50 19.55 19.60 19.65 19.70 19.75 19.80
10000
20000
30000
40000
50000
60000
70000
80000
90000
100000
110000
120000
130000
Time-->
Abundance TIC: G6P.D
40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460 480
0
2000
4000
6000
8000
10000
12000
14000
16000
m/z-->
Abundance
73
387
299
147
357
217
129 247
103 191 331 471
28155 173 407
Figure B.13: GC/MS data for glucose 6-phosphate
File       :H:\GCMS RESULTS\NING 12 330\GA D
Operator   :  
Acquired   : 31 Mar 2012  13:29     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: std GA                                          
Misc Info  : metabolite standards analysis                   
Vial Number: 24
8.608.628.648.668.688.708.728.748.768.788.808.828.848.868.888.908.928.948.968.989.009.029.049.06
1000000
2000000
3000000
4000
5000000
6000000
7000000
Time-->
Abundance TIC: GA.D
  8.84
40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400
0
100000
200000
300000
400000
500000
600000
700000
800000
900000
1000000
1100000
1200000
m/z-->
Abundance
73
147
292189
103 205
117
30759 131 175 221 32288 265237 395
Figure B.14: GC/MS data for glyceraldehyde
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File       :H:\GCMS RESULTS\NING 120330\GA3P.D
Operator   :  
Acquired   : 31 Mar 2012   4:22     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: std GA3P                                        
Misc Info  : metabolite standards analysis                   
Vial Number: 12
13.1513.2013.2513.3013.3513.4013.4513.5013.5513.6013.6513.7013.7513.8013.8513.9013.95
200000
400000
600000
800000
1000000
1200000
1400000
1600000
Time-->
Abundance TIC: GA3P.D
 13.59
40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420
0
20000
40000
60000
80000
100000
120000
m/z-->
Abundance
299
73
328
211
160
384133
101 227 400357
195 243175117 28357 267
Figure B.15: GC/MS data for glyceraldehyde 3-phosphate
File       :H:\GCMS RESULTS\NING 120330\Glc D
Operator   :  
Acquired   : 31 Mar 2012   8:10     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: std Glc                                         
Misc Info  : metabolite standards analysis                   
Vial Number: 17
15.25 15.30 15.35 15.40 15.45 15.50 15.55 15.60 15.65 15.70 15.75 15.80 15.85 15.90 15.95
200000
400000
600000
800000
1000000
1200000
1400000
Time-->
Abundance TIC: Glc.D
 15.53
 15.70
40 60 80 100120140160180200220240260280300320340360380400420440460480500520540560
0
20000
40000
60000
80000
100000
120000
140000
160000
m/z-->
Abundance
73
319
205
147
103
229
291 364262177 343 466390 55412652
Figure B.16: GC/MS data for glucose
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APPENDIX B: Mass Spectrometry Library
File       :H:\GCMS RESULTS\NING 120330\Glc13C.D
Operator   :  
Acquired   : 30 Mar 2012  21:32     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: std glucose 13C6                                
Misc Info  : metabolite standards analysis                   
Vial Number: 3
15.25 15.30 15.35 15.4015.45 15.50 15.55 15.6015.65 15.70 15.75 15.8015.85 15.90 15.95 16.00
200000
400000
600000
800000
1000000
1200000
1400000
1600000
1800000
2000000
Time-->
Abundance TIC: Glc13C.D
 15.53
 15.70
40 60 80 100120140160180200220240260280300320340360380400420440460480500520540560
0
20000
40000
60000
80000
100000
120000
140000
160000
m/z-->
Abundance
73
319
205
147
103
229
291 364262177 343 466390 55412652
Figure B.17: GC/MS data for glucose-13C6
File       :H:\GCMS results\ning 120404\e203.D
Operator   :  
Acquired   :  4 Apr 2012  21:51     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: ex 2.0.3                                        
Misc Info  : extracellular sample                            
Vial Number: 11
8.328.338.348.358.368.378.388.398.408.418.428.438.448.458.468.478.488.498.508.518.528.53
50000
100000
150000
200000
25
Time-->
Abundance TIC: e203.D
  8.41
50 60 70 80 90 100110120130140150160170180190200210220230240250260270280290300
0
10000
20000
30000
40000
50000
60000
70000
m/z-->
Abundance
174
73
147
248
86
13359 276100
117 158 299188 204 219
Figure B.18: GC/MS data for glycine
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APPENDIX B: Mass Spectrometry Library
File       :H:\GCMS RESULTS\NING 120330\Glyc.D
Operator   :  
Acquired   : 31 Mar 2012  10:27     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: std Glyc                                        
Misc Info  : metabolite standards analysis                   
Vial Number: 20
7.80 7.85 7.90 7.95 8.00 8.05 8.10 8.15 8.20 8.25 8.30 8.35 8.40 8.45 8.50 8.55 8.60 8.65
500000
1000000
1500000
2000000
2500000
Time-->
Abundance TIC: Glyc.D
  8.07
50 60 70 80 90 100110120130140150160170180190200210220230240250260270280290300310320
0
50000
100000
150000
200000
250000
300000
350000
400000
450000
m/z-->
Abundance
73
147
205
117
103
133 218
59 29919117789 163 314283263
Figure B.19: GC/MS data for glycerol
File       :H:\GCMS results\Ning 120330\Glyc3P.D
Operator   :  
Acquired   : 31 Mar 2012   1:20     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: std Gly3P                                       
Misc Info  : metabolite standards analysis                   
Vial Number: 8
13.75 13.80 13.85 13.90 13.95 14.00 14.05 14.10 14.15 14.20 14.25 14.30 14.35 14.40
200000
400000
600000
800000
100
1200000
1400000
1600000
18
2000000
2200000
Time-->
Abundance TIC: Glyc3P.D
 14.07
40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440
0
50000
100000
150000
200000
250000
m/z-->
Abundance
357
299
73
147
445
211101 387
129 256
328
193 283 41522855 177
Figure B.20: GC/MS data for sn-glycerol 3-phosphate
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APPENDIX B: Mass Spectrometry Library
File       :H:\GCMS RESULTS\NING 120330\Lac.D
Operator   :  
Acquired   : 31 Mar 2012  14:14     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: std Lac                                         
Misc Info  : metabolite standards analysis                   
Vial Number: 25
4.604.654.704.754.804.854.904.955.005.055.105.155.205.255.305.355.405.455.505.555.605.655.70
100000
200000
300000
400000
500000
600000
700000
800000
Time-->
Abundance TIC: Lac.D
  5.01
50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220
0
20000
40000
60000
80000
100000
120000
140000
m/z-->
Abundance
147
73
117
190
13359 21988
101 20351 175
Figure B.21: GC/MS data for lactate
File       :H:\GCMS results\ning 120402\321.D
Operator   :  
Acquired   :  2 Apr 2012  19:45     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: cell 3.2.1                                      
Misc Info  : cell samples                                    
Vial Number: 7
6.00 6.10 6.20 6.30 6.40 6.50 6.60 6.70 6.80 6.90 7.00 7.10 7.20 7.30 7.40 7.50 7.60 7.70 7.80 7.90 8.00 8.10
100000
200000
300000
400000
500000
600000
700000
Time-->
Abundance TIC: 321.D
50 60 70 80 90 100110120130140150160170180190200210220230240250260270280290300310320330340
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
50000
55000
60000
m/z-->
Abundance
158
73
147
59 86 116 232218132102
260170 299188 336207
Figure B.22: GC/MS data for leucine/isoleucine
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APPENDIX B: Mass Spectrometry Library
File       :H:\GCMS RESULTS\NING 120330\blank.D
Operator   :  
Acquired   : 30 Mar 2012  20:01     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: blank                                           
Misc Info  : control                                         
Vial Number: 1
14.00 14.10 14.20 14.30 14.40 14.50 14.60 14.70 14.80 14.90 15.00
500000
1000000
1500000
2000000
2500000
Time-->
Abundance TIC: blank.D
 14.49
50 60 70 80 90100110120130140150160170180190200210220230240250260270280290300310320330
0
50000
100000
150000
200000
250000
300000
350000
m/z-->
Abundance
312
73
120 135
149
50
32790 213 277106 196165 180 261 293229 244
Figure B.23: GC/MS data for myristic acid-d27 (internal standard)
File       :H:\GCMS results\ning 120402\413.D
Operator   :  
Acquired   :  2 Apr 2012  23:34     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: cell 4.1.3                                      
Misc Info  : cell samples                                    
Vial Number: 12
9.60 9.70 9.80 9.90 10.0010.1010.2010.3010.4010.5010.6010.7010.8010.9011.0011.1011.2011.3011.4011.50
100000
200000
300000
400000
500000
600000
700000
800000
Time-->
Abundance TIC: 413.D
40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440
0
20000
40000
60000
80000
100000
120000
140000
160000
m/z-->
Abundance
73
147
233
133
19055 101 175 335247217117 265 30732187 433161 350291
Figure B.24: GC/MS data for malic acid
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APPENDIX B: Mass Spectrometry Library
File       :H:\GCMS results\ning 120404\e203.D
Operator   :  
Acquired   :  4 Apr 2012  21:51     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: ex 2.0.3                                        
Misc Info  : extracellular sample                            
Vial Number: 11
10.95 11.00 11.05 11.10 11.15 11.20 11.25 11.30 11.35 11.40 11.45 11.50 11.55
100000
200000
300000
400000
500000
600000
700000
800000
Time-->
Abundance TIC: e203.D
 11.26
50 60 70 80 90 100110120130140150160170180190200210220230240250260270280290300
0
5000
10000
15000
20000
25000
30000
m/z-->
Abundance
176
73
128
61
147
219 293
250100 114 160 20218884 232 26350 278
Figure B.25: GC/MS data for methionine
File       :H:\GCMS RESULTS\NING 330\PEP D
Operator   :  
Acquired   : 30 Mar 2012  22:18     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: std PEP                                         
Misc Info  : metabolite standards analysis                   
Vial Number: 4
12.00 12.05 12.10 12.15 12.20 12.25 12.30 12.35 12.40 12.45
100000
200000
300000
400000
500000
600000
700000
Time-->
Abundance TIC: PEP.D
 12.21
40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380
0
10000
20000
30000
40000
50000
60000
70000
m/z-->
Abundance
369
73
147
211
299
133
225
384243195 315181 28559 115 26616789 329
Figure B.26: GC/MS data for phosphoenolpyruvate
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APPENDIX B: Mass Spectrometry Library
File       :H:\GCMS results\ning 120404\e203.D
Operator   :  
Acquired   :  4 Apr 2012  21:51     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: ex 2.0.3                                        
Misc Info  : extracellular sample                            
Vial Number: 11
10.95 11.00 11.05 11.10 11.15 11.20 11.25 11.30 11.35 11.40 11.45 11.50 11.55
100000
200000
300000
400000
500000
600000
700000
800000
Time-->
Abundance TIC: e203.D
 11.26
50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230
0
5000
10000
15000
20000
25000
30000
35000
40000
m/z-->
Abundance
120
75 146
91
130
103
65 22220417451 158 194186
Figure B.27: GC/MS data for phenylalanine
File       :H:\GCMS results\ning 120402\423.D
Operator   :  
Acquired   :  3 Apr 2012   1:50     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: cell 4.2.3                                      
Misc Info  : cell samples                                    
Vial Number: 15
10.2010.4010.6010.8011.0011.2011.4011.6011.8012.0012.2012.4012.6012.8013.0013.2013.4013.6013.80
100000
200000
300000
400000
500000
600000
700000
800000
Time-->
Abundance TIC: 423.D
40 50 60 70 80 90100110120130140150160170180190200210220230240250260270280290300310320330340350360
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
100000
110000
120000
m/z-->
Abundance
156
73
258230
59 133 207104 119 19186 299310273 324172 243 359
Figure B.28: GC/MS data for proline
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APPENDIX B: Mass Spectrometry Library
File       :H:\GCMS RESULTS\NING 120330\Pyr.D
Operator   :  
Acquired   : 31 Mar 2012  12:43     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: std Pyr                                         
Misc Info  : metabolite standards analysis                   
Vial Number: 23
4.65 4.70 4.75 4.80 4.85 4.90 4.95 5.00 5.05 5.10 5.15 5.20
50000
100000
150000
200000
250000
Time-->
Abundance TIC: Pyr.D
50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
m/z-->
Abundance
73
174
59
89
115
99
158
52 189143 207130
Figure B.29: GC/MS data for pyruvate
File       :H:\GCMS RESULTS\NING 12033 \R5P.D
Operator   :  
Acquired   : 30 Mar 2012  23:49     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: std R5P                                         
Misc Info  : metabolite standards analysis                   
Vial Number: 6
17.35 17.40 17.45 17.50 17.55 17.60 17.65 17.70 17.75 17.80 17.85
200000
400000
600000
800000
1000
1200000
1400000
1600000
1800000
2000000
220
Time-->
Abundance TIC: R5P.D
 17.58
40 60 80 100120140160180200220240260280300320340360380400420440460480500520
0
20000
40000
60000
80000
100000
120000
140000
160000
180000
200000
220000
240000
m/z-->
Abundance
315
73
217
147
357
403
459
101 272191126 168 431243 51753 291 376
Figure B.30: GC/MS data for ribose 5-phosphate
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APPENDIX B: Mass Spectrometry Library
File       :H:\GCMS RESULTS\NING 120330\Ru5P.D
Operator   :  
Acquired   : 31 Mar 2012   2:51     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: std Ru5P                                        
Misc Info  : metabolite standards analysis                   
Vial Number: 10
17.30 17.35 17.40 17.45 17.50 17.55 17.60 17.65 17.70 17.75 17.80 17.85 17.90
200000
400000
600000
800000
1000000
1200000
1400000
1600000
1800000
Time-->
Abundance TIC: Ru5P.D
 17.53
 17.69
40 60 80 100120140160180200220240260280300320340360380400420440460480500520540560580
0
50000
100000
150000
200000
250000
300000
350000
400000
m/z-->
Abundance
357
73
299
147
387217103 331262191 429240 482170125 529 573
Figure B.31: GC/MS data for ribulose 5-phosphate
File       :H:\GCMS results\ning 120402\423.D
Operator   :  
Acquired   :  3 Apr 2012   1:50     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: cell 4.2.3                                      
Misc Info  : cell samples                                    
Vial Number: 15
6.60 6.80 7.00 7.20 7.40 7.60 7.80 8.00 8.20 8.40 8.60 8.80 9.00 9.20 9.40 9.60 9.80
200000
400000
600000
800000
1000000
1200000
1400000
Time-->
Abundance TIC: 423.D
50 60 70 80 90 100110120130140150160170180190200210220230240250260270280290300310320330340
0
20000
40000
60000
80000
100000
120000
140000
160000
180000
m/z-->
Abundance
73
132116
147
57 103
219
234159
18888 206174 336299
Figure B.32: GC/MS data for serine
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APPENDIX B: Mass Spectrometry Library
File       :H:\GCMS results\ning 120402\321.D
Operator   :  
Acquired   :  2 Apr 2012  19:45     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: cell 3.2.1                                      
Misc Info  : cell samples                                    
Vial Number: 7
9.40 9.50 9.60 9.70 9.80 9.90 10.00 10.10 10.20 10.30 10.40 10.50 10.60 10.70 10.80
50000
100000
150000
200000
250000
300000
350000
Time-->
Abundance TIC: 321.D
50 60 70 80 90 100110120130140150160170180190200210220230240250260270280290300310320
0
5000
10000
15000
20000
25000
m/z-->
Abundance
75
218
117
147
291
86 101 172
59 133 203 320301191158 230
Figure B.33: GC/MS data for theronine
File       :H:\GCMS results\ning 1204 4\e203.D
Operator   :  
Acquired   :  4 Apr 2012  21:51     using AcqMethod NING 120315        
Instrument :    Instrumen
Sample Name: ex 2.0.3                                        
Misc Info  : extracellular sample                            
Vial Number: 11
7.00 7.05 7.10 7.15 7.20 7.25 7.30 7.35 7.40 7.45
200000
400000
600000
800000
1000000
1200000
14000 0
1600000
Time-->
Abundance TIC: e203.D
  7.18
50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260
0
50000
100000
150000
200000
250000
300000
350000
400000
450000
m/z-->
Abundance
144
73
218
10059 133 156 24611486 203174 189 230 260
Figure B.34: GC/MS data for valine
144
Appendix C: Attached File
The mathematical model as a gPROMS file is attached to this PDF file electroni-
cally as an attachment.
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